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Abstract
In Eastern and Southern Africa, hard-to-reach populations (e.g., long distance truck drivers and
female sex workers), defined as populations that are difficult to interact or engage with due to
their unique behaviors and characteristics, are disproportionately affected by the HIV epidemic
and are at high-risk of acquiring and transmitting HIV. Further, these populations have
substantially low uptake of HIV testing services, and those that have been diagnosed with HIV
and on antiretroviral therapy experience high loss-to-follow-up from treatment programs.

Hard-to-reach populations face unique barriers in accessing and utilizing routine HIV care such
as provider stigmatization towards sex workers and highly mobile nature of their occupations.
Innovative and targeted strategies, which may be resource-intensive, are required to improve
their engagement and retention in care. Evidence on cost-effective strategies to improve HIV
testing uptake and to reduce loss to follow-up from HIV treatment programs in hard-to-reach
populations in Eastern and Southern Africa remains limited.

This dissertation is comprised of three papers examining the cost-effectiveness of HIV testing
and loss to follow-up strategies among hard-to-reach populations in Eastern and Southern Africa,
using female sex workers and long-distance truck drivers as case study populations and Kenya as
a case study setting. In paper one, I conducted a trial-based cost-effective analysis of offering the
choice to HIV self-test compared to provider-administered HIV testing among long-distance
truck drivers in Kenya. Paper two extended the analysis for paper one by examining the costeffectiveness of a broad range of alternative HIV testing strategies among hard-to-reach
populations in Eastern and Southern Africa using a lifetime Markov model. Seven strategies
were examined: i) No testing, ii) voluntary counseling and testing, iii) provider-initiated and -
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administered testing, delivery of: iv) self-testing kits, v) self-testing coupons, and vi) HIV testing
referral cards in the community using peer-educators, and vii) offering a choice of self-testing at
the health facility. In paper three, I applied the same Markov model from paper two to examine
strategies to prevent loss to follow-up among female sex workers on antiretroviral therapy in
Eastern and Southern Africa. Strategies included: 1) No intervention; 2) Home ART delivery
using community-health workers; 3) Home ART delivery using community-health workers plus
monthly nutrition supplement; 4) physical and phone-tracing of patients that miss an
appointment plus transport refund to the health facility; 5) physical and phone-tracing with free
medical care for opportunistic infections; 6) free medical care for opportunistic infections with
transport refund to the health facility and free breakfast. Data for paper one came from a
randomized controlled trial (n=150, intervention; n=155, control), while data for paper two and
three came from peer-reviewed and grey literature. All costs were reported in 2017 international
dollars in paper one and 2017 US dollars for paper two and three.

Findings from these studies suggest that investing resources in strategies that offer choices in
HIV testing approaches such self-testing at the health facility or in communities using peer
educators would improve HIV testing uptake and reaching out to patients on treatment in their
communities to deliver them ART drugs may improve retention in ART programs in Eastern and
Southern Africa. In paper one, I found that offering a choice of HIV self-testing at the clinic was
cost-effective compared to only the provider-administered HIV testing with an incremental costeffectiveness ratio (ICER) equal to $163. In paper two, delivery of HIV self-testing kits in the
community using peer educators was cost-effective (ICER < $600) in both truck drivers and
female sex worker sub-populations. Finally, in paper three, delivery of antiretroviral therapy
drugs to female sex workers in the community was cost-effective (ICER < $500).
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Chapter I: Introduction
In Eastern and Southern Africa, hard-to-reach populations (e.g., long distance truck drivers and
female sex workers), which are defined as populations that are difficult to interact or engage with
due to their unique behaviors and characteristics,1 are disproportionately affected by the HIV
epidemic, with HIV prevalence of five times more than that in the general population. 2–7
Additionally, hard-to-reach populations are at high-risk of acquiring and transmitting HIV but
have substantially low uptake of HIV testing services,2,5,8–10 and those that have been diagnosed
with HIV and on antiretroviral therapy (ART), experience higher (53%) loss to-follow-up
(LTFU) from treatment programs11–18 compared to people living with HIV (PLWH) in the
overall population (14%).19

Awareness of HIV status has downstream implications for timely linkage to care, ART initiation,
and viral suppression, which are critical for achieving the UNAIDS goal of ending the HIV
epidemic by 2030.20 However, hard-to-reach populations face unique barriers that impact their
accessibility and utilization of care including HIV testing. For example, truck drivers are highly
mobile with irregular work schedules and hours that are discordant with healthcare facility
opening hours.3 Evidence suggests that differentiated approaches such as oral self-administered
HIV testing at healthcare facilities21 and delivery of HIV self-testing kits to targeted populations
in the communities22 are effective at improving HIV testing uptake among hard-to-reach
populations due to their acceptability, flexibility and privacy.23–26 Although the effectiveness of
these approaches particularly in hard-to-reach populations is still emerging, little is known about
their value for money.
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Hard-to-reach populations are not only hard-to-reach but among those able to be reached,
diagnosed with HIV, and initiated on ART experience high LTFU from care—opting out of care
for more than 180 days without being classified as either dead or transferred to another ART
clinic or program.19 For example, female sex workers are at high-risk of LTFU due to fear of
being identified and to provider stigmatization, which may impact routine utilization of care and
retention in HIV care among those living with HIV.27 Identifying cost-effective strategies to
reduce LTFU is critical for improving HIV-related morbidity and mortality, preventing new HIV
transmission, and for efficiency in allocation of scarce resources. No strategies have been
examined to reduce LTFU among hard-to-reach populations in Eastern and Southern Africa.

This dissertation focused on efficiency in allocation of resources for HIV response including
HIV testing and reduction of LTFU for those on ART among hard-to-reach populations in
Eastern and Southern Africa. HIV response programs in low- and middle-income countries are
largely funded by global donors. Given the recent HIV funding constraints, with more than half
of high-income countries reducing their funding for HIV response programs to low-income
countries,28 it is critical for local policy makers to allocate scarce resources efficiently by
investing in cost-effective strategies.

The goal for this dissertation was to identify cost-effective strategies to diagnose hard-to-reach
individuals living with HIV and retain them in HIV care. HIV testing is the first stage along the
HIV care continuum, in papers one and two, I examined the cost-effectiveness of strategies to
improve HIV testing uptake among those who are undiagnosed and to engage them in care. Once
engaged in care and initiated on ART, it is important to retain people living with HIV in care. In
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paper three, I examined the cost-effectiveness of strategies to reduce LTFU among those in HIV
care and on ART.

Paper one
I conducted a trial-based cost-effectiveness analysis of offering the choice of HIV self-testing at
the healthcare facility to increase HIV testing uptake among truck drivers compared to provideradministered HIV testing only, which is the standard of care. This study was based on a
randomized controlled trial conducted in 2015 in Kenya among truck drivers at two roadside
clinics. In the trial, participants (n=150) in the intervention arm were offered the choice to test
for HIV using (1) the provider-administered HIV testing or (2) HIV self-testing under the
supervision of a provider. Those who declined the two options were offered a third choice (3)
HIV self-testing at home without supervision of a provider. Participants (n=155) in the control
arm were offered the provider-administered HIV testing only. The primary outcome in the trial
was HIV testing uptake, defined as a participant that accepts to be tested for HIV. Participants in
the intervention (CHIVST) arm had significantly higher odds of testing for HIV compared to the
control (SOC) arm (2.8, 95% Confidence Intervals [1.5, 5.4]).21

Effectiveness data came from a randomized-controlled trial of CHIVST versus provideradministered blood (finger-prick) testing only at a roadside wellness clinic in Kenya. Economic
cost data came from the literature, reflecting a societal perspective. Generalized Poisson and
linear gamma regression models were used to estimate the effectiveness and incremental costs
(2017 I$), respectively; incremental effectiveness was reported as the number needed to receive
CHIVST for an additional HIV test uptake. I evaluated the performance of incremental costeffectiveness ratios (ICERs) using a willingness-to-pay threshold of 3xGDP per capita for Kenya
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and assessed uncertainty using deterministic sensitivity analyses and the cost-effectiveness
acceptability curve.

HIV test uptake was 23% more likely for CHIVST versus SOC, with six individuals needed to
receive CHIVST for an additional HIV test uptake. The mean cost per patient was over fourfold
higher for CHIVST versus SOC (I$35.59 vs I$8.84). CHIVST was I$ 163.77, 95% CI [151.57,
175.37] per additional HIV test uptake compared to SOC. Self-test kit and cell service were the
main cost drivers of the ICER, with findings robust even in a worst-case scenario (highest
possible costs). The probability of CHIVST being cost-effective approached one at willingnessto-pay of I$250. CHIVST was cost-effective at a low willingness-to-pay threshold ($163),
suggesting that CHIVST is a highly efficient use of resources for improving HIV test uptake
among high-risk sub-populations. Policies supporting CHIVST and similar sub-populations may
expedite achievement of international targets.

Paper two
In paper two, I extended the analysis for the first paper and examined the cost-effectiveness of a
broad range of alternative HIV testing strategies in hard-to-reach populations in Eastern and
Southern Africa. Seven alternative HIV testing strategies were examined: i) No testing; ii)
voluntary counseling and testing (VCT);29 iii) provider-initiated and -administered testing and
counseling (PITC);21 delivery of: iv) self-testing kits, v) self-testing coupons, and vi) HIV testing
referral cards in the community using peer-educators;22 and vii) offering a choice of self-testing
at the health facility in addition to provider-initiated and -administered testing.21 I developed a
lifetime Markov model to examine life years saved, disability adjusted life years (DALYs)
averted, economic costs, and incremental cost-effectiveness ratios in a cohort of 30-year-old
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high-risk and hard-to-reach men and women living with HIV. Economic costs were estimated
from a societal perspective and reported in 2017 US dollars. The cost-effectiveness of strategies
was determined according to the willingness to pay threshold equivalent to 3xGDP per capita for
Kenya in 2017 (3x$1,570 = $4,710). Future costs and health benefits were discounted at an
annual rate of 3%. Deterministic sensitivity analysis was performed to assess uncertainty in
model parameter inputs.

I found that the Kit delivery strategy was cost-effective and had the highest cost and life
expectancy at 30 years and lowest DALYs lost among female sex workers (FSWs) and truck
drivers. Total costs ranged from $1,400 to $6,100 and $1,400 to $4,951 in the “No testing” and
kit delivery strategies among FSWs and truck drivers, respectively. More DALYs were lost in
the “No testing” strategy (21.93 and 22.11) compared to the Kit delivery strategy (12.70 and
14.77) among FSWs and truck drivers, respectively. The kit delivery strategy was cost-effective
compared to alternative HIV testing strategies among both FSWs and truck drivers with an ICER
of less than $600 per DALY averted. The kit delivery strategy compared to No testing, cost more
but averted 9.23 and 7.34 DALYs and saved 8.88 and 7.13 life years among FSWs and truck
drivers, respectively. Delivery of self-testing kits in the community was cost-effective among
FSW when 75% or more are reached. Variations in parameter inputs did not change the main
findings among truck drivers. Using peer-educators to deliver HIV self-testing kits in the
community is a cost-effective strategy to improve HIV test uptake in populations that are hard to
reach and at high-risk of acquiring and transmitting HIV.
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Paper three
In the third paper, I examined the cost-effectiveness of alternative strategies to reduce LTFU
among female sex workers on ART in Eastern and Southern Africa. Using a similar Markov
model from paper two, I projected costs and DALYs for six alternative strategies: 1) No
intervention; 2) Home ART delivery using community-health workers; 3) Home ART delivery
using community-health workers plus monthly nutrition supplement; 4) physical and phonetracing of patients that miss an appointment plus transport refund to the health facility; 5)
physical and phone-tracing with free medical care for opportunistic infections; 6) free medical
care for opportunistic infections with transport refund to the health facility and free breakfast.
The analysis was conducted from a payer perspective with future DALYs lost and costs
discounted at 3%. Costs were valued in US dollars and inflation-adjusted to 2017 currency year.
The ICER was used to assess the relative performance of the strategies, with the costeffectiveness of a given strategy determined according to a threshold of 3x the GDP per capita
for Kenya in 2017 (3x$1,570 = $4,710). Uncertainty in inputs was assessed using probabilistic
sensitivity analysis.

In the base case analysis, total costs and DALYs lost per strategy ranged from $2,994 to $10,022
and 11.52 to 9.27 for No Intervention and ART delivery plus nutrition supplement, respectively.
ART delivery was cost-effective compared to alternative strategies with an ICER of $470 per
DALY averted. Although ART delivery with nutrition supplement had lower DALYs lost (9.27),
total costs were substantially higher compared to the next best alternative, ART delivery
($10,022 vs $5,173). Tracing with transport refund had higher costs ($4,386 vs $3,460) and
DALYs lost (11.05 vs 10.55) compared to the next best alternative, ART delivery, and was
absolutely dominated. Strategies: tracing with free medical care for opportunistic infections and
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transport refund with free medical care for opportunistic infections plus breakfast had lower
costs ($4,606 and $5,173) but higher DALYs lost (10.51 and 10.35) and were extendedly
dominated by ART delivery with nutrition supplement that had higher costs ($10,022) but with
lower DALYs lost (9.27). FSWs remain disproportionately impacted by HIV with high rates of
LTFU from ART programs among those on treatment. I found that delivering ART drugs to
FSWs in their homes, places that they frequent, or community centers was a cost-effective
strategy to reduce LTFU among patients in FSWs in ART programs in Eastern and Southern
Africa
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Chapter II: Choice of Self-Administered Oral HIV Testing among
Long Distance Truck Drivers in Kenya: A Trial-based Costeffectiveness Analysis
Introduction
The HIV epidemic in sub-Saharan Africa remains a major global public health challenge, with
over 1 million people living with HIV in the region unaware of their HIV status. 30 Early
awareness of HIV status has downstream implications along the care continuum, including
timely linkage to care, antiretroviral therapy (ART) initiation, and viral suppression, which are
critical for achieving the international targets that can end the HIV epidemic. 31 However, uptake
of HIV testing services is low, particularly in sub-populations that are disproportionately
impacted by HIV and at high risk of transmission.2,5,8 To improve and sustain high HIV
awareness levels in these sub-populations, targeted, innovative HIV testing strategies are needed.
These strategies may require more resources,32 a significant challenge when HIV funding is
limited.33

Long distance truck drivers in the region are at high risk of acquiring and transmitting HIV, but
have relatively low HIV testing uptake.2,5,8 For example, from 2013 to 2015, only 32% of 13,252
patients that visited the clinics utilized HIV-related services including HIV testing.8 In 2018, the
North Star Alliance—an organization providing healthcare services to mobile workers and
people they interact with along truck routes—reported that only 34% of 289,078 services offered
at wellness centers were HIV testing,34 indicating that HIV testing uptake is still sub-optimal
even when healthcare facilities are geographically close to places where truckers congregate such
as truck stops.
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This sub-population has unique characteristics contributing to their high HIV risk and low-test
uptake. Truck drivers travel for many days away from their main partners, which provides
opportunities to engage with other partners and commercial sex workers,35–37 increasing their
HIV risk.38 Truck driver mobility coupled with irregular work schedules and discordance
between work hours and healthcare facility opening hours limit the accessibility and utilization
of healthcare services, including routine HIV testing. 39 Further, men are less likely to test for
HIV and, given that majority of truck drivers are men, there is an additional gender barrier to
HIV testing uptake.40 Standard of care approaches for HIV testing, such as clinic-based,
provider-administered testing, do not address these barriers.

Emerging evidence suggests that patient-centered care delivery, including self-administered oral
HIV testing,41 improves HIV test uptake among truck drivers.21,42 One approach—selfadministered oral HIV testing—has generated considerable interest due to its acceptability,
flexibility and user privacy.23–26 The introduction of HIV self-testing to compliment the
traditional standard of care—provider administered HIV testing—has improved uptake of HIV
testing, both in the general population23,43 and among high-risk sub-populations including truck
drivers21,22,42 and sex workers22,44 in sub-Saharan Africa.
While HIV self-testing has been found to be effective,21 evidence on cost32 and costeffectiveness45–48 is limited and no cost-effectiveness study exists among high-risk subpopulations including truck drivers. Examining cost-effectiveness is particularly pertinent in
resource-limited settings where in-country resources are often insufficient to implement all HIV
response programs and may potentially worsen since the global HIV funding in recent years has
decreased or remained flat33,49 and emerging external shocks (e.g., COVID-19) threaten the
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availability of ongoing donor support.50 This funding shortfall and ongoing future financing
challenges underscore the need to prioritize available resources for cost-effective interventions.

In Kenya, a recent randomized controlled trial found that offering truck drivers the choice of
self-administered oral HIV-testing versus provider-administered testing at an easily accessible
roadside wellness clinic resulted in HIV testing uptake nearly three times that of provideradministered testing only, suggesting HIV testing approaches that are tailored to individual need
or preference in this sub-population are effective.21 While this trial found the intervention
effective, there is little knowledge of its value for money in this sub-population. This study
examined the incremental cost-effectiveness of offering the choice of HIV self-testing (CHIVST)
compared to provider-administered HIV testing, the standard of care (SOC) only, among truck
drivers presenting for care at a roadside wellness clinic in Kenya. Two research questions are
examined: 1) are economic costs of offering the CHIVST greater than the SOC? 2) is offering
the CHIVST a cost-effective intervention compared to the SOC?

Overview of the trial
In 2015, a randomized controlled trial was conducted at two roadside wellness clinics in Kenya
to compare HIV testing uptake among truck drivers offered the choice of self-administered rapid
oral HIV-testing compared to uptake among those offered provider-administered rapid blood
(finger-prick) HIV testing only, the standard of care (SOC).21 In the intervention arm, truck
drivers (n=150) were offered the choice to test for HIV using 1) the SOC HIV testing or 2) selfadministered oral HIV-testing under the supervision of a provider. If the truck driver declined the
two options, they were offered a third option; 3) self-administered oral HIV-testing outside the
clinic (at home) without supervision of a provider but with phone-based support and post-test
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counseling. In the control arm, truck drivers (n=155) were offered only the SOC HIV testing.
The adjusted odds ratio (2.8, 95% CI [1.5, 5.4]) of HIV testing uptake in the intervention arm
were significantly higher compared to the control arm.21

Methods
Overview
I conducted a trial-based incremental cost-effectiveness analysis of offering the CHIVST to
increase HIV testing uptake among truck drivers in Kenya compared to the SOC. Data from the
trial was used to estimate the effectiveness and incremental effectiveness of offering the
CHIVST, with incremental effectiveness estimated as the number of participants needed to
receive the CHIVST for an additional truck driver to test for HIV. Economic cost data were
derived from the literature according to the societal perspective, which considers economic costs
for both the payer and the patient. Incremental cost-effectiveness ratios were calculated, with the
economic performance of the CHIVST intervention evaluated according to a threshold of 3 x
gross domestic product (GDP) per capita in Kenya. I assessed uncertainty using deterministic
sensitivity analyses and a cost effectiveness acceptability curve. This study was reviewed by the
Virginia Commonwealth University Institutional Review Board and designated as exempt to
regulations of human subject (Reference Number: HM20015160).

Costing Approach
Economic cost data came from the literature. Studies conducted in Kenya were prioritized, with
data from studies conducted in lower-middle-income countries in sub-Saharan Africa also
considered if they were contextually relevant to the trial. I restricted the search to studies with
data collected less than 10 years from the year of the trial, since more recent cost data sources
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reflect current healthcare delivery systems and utilization patterns, which tend to vary overtime.
Costs were adjusted for inflation using the World Bank GDP deflator51 to account for changes in
costs over time and reported in 2017 international dollars (I$),52 which enables comparison of
costs across multiple settings (countries) and captures differences in local currency purchasing
power. Micro- and gross costing approaches were used to assign per-patient costs. Micro-costing
enables more precise estimation of costs (medical, labor and patient time) for resources utilized53
by multiplying the quantity of resources and the unit cost. Gross-costing aggregates costs
(equipment, capital, cell phone service, overhead costs) for an intervention to estimate the per
patient cost for resources that cannot be explicitly allocated at the patient level based on
individual utilization.54

Data
Costs were estimated based on the HIV testing procedure (SOC or oral self-test) performed
and/or the setting (clinic only or clinic and home). Medical costs included the cost of HIV testing
kits (OraQuick for self-test, I$ 15.5255; Colloidal Gold test for SOC, I$ 1.4356) as well as medical
supplies (self-test, I$ 0.26; SOC, I$ 0.42) used in the HIV testing process at the clinic,57 which
varied based on the HIV testing procedure. Medical supplies considered are listed in the
supplementary material, Table S11. I emphasize that the cost of the SOC test kit was only
considered in the sensitivity analysis, since SOC kits were provided to North Star Alliance by the
Kenyan Ministry of Health and thus the trial did not incur the cost for these kits.55 Labor costs
included salaries for the nurse per-patient (self-test, I$ 2.84; SOC, I$ 2.27),55 non-clinical
healthcare facility staff (I$ 1.10 per-patient that tested from the clinic only; I$ 0.47 per-patient
that visited the clinic but tested from home)32 and one-time training (I$ 0.09 per-patient in the
intervention arm) for nurses on how to use the HIV self-testing kit.55 Equipment (cell phone, I$
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2.47 per-patient in the intervention arm),55 healthcare facility site (I$ 1.72 per-patient that tested
from the clinic only; I$ 0.74 per-patient that visited the clinic but tested from home),32 overhead
(I$ 4.24 per-patient that tested at the clinic only; $I 2.26 per-patient that visited the clinic but
tested from home)32 and cell phone service (13.65 per-patient in the intervention arm)55 costs
were allocated using the gross-costing.54 Patient time spent at the healthcare facility or home
testing for HIV, including pre- and post-test counseling, was considered time lost that could have
been alternatively used to economically benefit the patient; patient time (oral self-test, I$ 3.13;
SOC, I$ 2.51) was calculated as the product of the time spent testing for HIV and the hourly
wage of a truck driver, estimated based on income of participants in trial.21 The HIV testing
process took 40 and 50 minutes for participants that tested using the standard of care and oral
self-administered test, respectively.55

Statistical analysis
I conducted analysis using two statistical models. A generalized linear Poisson regression model
with a robust variance was used to estimate the effectiveness and incremental effectiveness of
CHIVST and a generalized linear gamma regression model to estimate the incremental cost.
Equation 1 below shows the generalized linear model for estimating effectiveness, incremental
effectiveness, and incremental costs of the CHIVST.
𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖 = 𝛽𝑜 + 𝛽1 𝐶ℎ𝑜𝑖𝑐𝑒𝑖 + 𝑿𝒊 𝑩 + 𝑢𝑖

(1)

where, 𝑂𝑢𝑡𝑐𝑜𝑚𝑒𝑖 represents HIV testing uptake or cost assigned to the 𝑖 𝑡ℎ patient; 𝐶ℎ𝑜𝑖𝑐𝑒𝑖 is a
binary variable equal to 1 if a patient is assigned to CHIVST arm and equal to 0 if assigned to the
SOC; 𝛽1 is the coefficient of interest—effect of CHIVST on the outcome. 𝑿𝐢 and 𝜝 are vectors
and coefficients, respectively, of the control variables. I controlled for four variables that have
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been found to impact HIV testing uptake40 and/or are contextually applicable to the study. These
include the healthcare facility (the trial was conducted at two facilities), age of the participant,
whether the participant visited the clinic to purposely test for HIV, and whether they have paid of
sex in the last 6-months prior to the date of the clinic visit.

Effectiveness and Incremental Effectiveness
I estimated the effectiveness of CHIVST as the relative risk of HIV test uptake in the CHIVST
arm compared to the SOC arm. The incremental effectiveness was estimated as the Number
Needed to Treat (NNT)58 and interpreted as the number of truck drivers who need to be offered
the CHIVST for an additional driver to get tested for HIV. The NNT approach was selected as an
alternative to more traditional measures of incremental effectiveness such as the disability
adjusted life years (DALYs) averted because the primary outcome (HIV test uptake) in the trial
was an intermediate outcome and the trial time period (3 months) was too short to estimate
DALYs. Using DALYs as a measure of health benefit would not have generated meaningful
differences between trial arms and multiple assumptions would be required to estimate when
considering a longer time horizon without developing a mathematical model.

NNT was derived in four steps:
•

Step 1: Predict the absolute risk of HIV testing uptake per patient.

•

Step 2: Calculate the mean per-patient absolute risk for HIV testing uptake per trial arm.

•

Step 3: Estimate the mean per-patient absolute risk difference between trial arms

•

Step 4: Take the reciprocal of the mean absolute risk difference to calculate NNT.
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Economic Costs and Incremental Costs
Economic costs per-patient by trial arm were calculated by multiplying resources utilized at the
individual level with unit costs and summarized using the mean with 95% confidence intervals
(CIs), since decisions are made based on expected costs.59 Incremental costs reflect the
difference in mean per-patient costs between the CHIVST and SOC arms.

Incremental Cost-effectiveness Ratio (ICER)
The ICER was calculated as the product of the incremental cost and incremental effectiveness.
Conventionally, the ICER is calculated by dividing the incremental cost (C) by incremental
𝐶

effectiveness (E) i.e., 𝐼𝐶𝐸𝑅 = 𝐸. When using the NNT approach, however, the incremental
effectiveness (NNT) is calculated as the reciprocal of the mean per-patient absolute risk
1

1

difference (RD). Thus, the ICER is calculated as the product of C and NNT (ICER = C ∗ RD =
C ∗ NNT). I calculated the 95% CI for the ICER using non-parametric bootstrapping method
since the data (cost and effectiveness variables) were not normally distributed.59

A threshold of 3 x GDP per capita (2017) for Kenya was used to determine the cost-effectiveness
of the CHIVST.60 The threshold represents the maximum willingness-to-pay (WTP) value for the
additional health benefit gained from the CHIVST and is used to determine whether CHIVST
presents a good value for money. The willingness-to-pay threshold is used as guide for costeffectiveness decision making, in addition to other factors including local competing priorities,
intervention affordability, and feasibility of implementation, which are not accounted for in the
willingness-to-pay threshold.61,62 I also assessed a lower threshold (GDP per capita) to account
for differences in affordability across settings given that the threshold of 3xGDP per capita may
be too high for low-income countries with resource constraints and high opportunity cost.61–64
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Missing data
In the analytic sample, only 9 (3%) participants were missing at least one data point. Using
Little’s test, I examined the randomness assumption about the missing data and found that the
data were missing completely at random (MCR) across trial arms,65 implying that the missing
data were not systematically correlated with other variables across trial arms. Participants (9)
with data MCR were then excluded from the analysis since they had no significant impact on the
study outcomes.

Uncertainty
I assessed the impact of variation in costs on the ICER using deterministic sensitivity analyses
(one-way and multi-way sensitivity analysis)60 and uncertainty in the base case ICER using the
cost-effectiveness acceptability curve.66,67 One-way sensitivity analysis identified the main cost
drivers of variation in the ICER, with the results reported using a tornado diagram, which
summarizes of the range of ICERs due to variation in unit cost estimates. Multi-way sensitivity
analysis assessed the robustness of the study findings by varying unit costs considering the bestand worst-case scenarios. The worst-case scenario was defined according to the upper bound
values, while the best-case scenario was defined as the lower bound values of each economic
cost. Although these scenarios may be unrealistic in practice, they can provide insight into the
policy impact of the most optimistic and pessimistic cases in cost variation. I assessed
uncertainty in the base case ICER using the cost-effectiveness acceptability curve. The
acceptability curve summarizes the probability an intervention is cost-effective at different
willingness-to-pay thresholds. I generated the acceptability curve from a joint distribution of
incremental costs and incremental effects, which was estimated using non-parametric
bootstrapping.67
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Results
Base case analysis
CHIVST significantly increased HIV testing uptake among truck drivers. More than 87%
(130/149) of truck drivers in the CHIVST arm tested for HIV compared to 73% (114/156) in the
SOC arm. Truck drivers in the CHIVST arm were 23% more likely to test for HIV relative to
those in the SOC arm. The incremental effectiveness, measured as the NNT, was 6.25, 95% CI
[5.00, 8.33], meaning that for every six truck drivers offered the CHIVST, one additional driver
will test for HIV.

The mean cost per-patient (Table 1) was more than four times higher in the CHIVST (I$ 35.59 vs
SOC (I$ 8.84) arm. Majority (>70%) of the mean per-patient cost in the CHIVST was attributed
to the cell phone service (I$ 12.03), price of HIV testing kit (I$ 10.12) and overhead (I$ 3.59),
while in the SOC arm, it was attributed to the overhead (I$ 3.06), patient time (I$ 1.81) and nurse
salary (I$ 1.64). The incremental cost was I$26.20, 95% CI [23.32, 29.09], representing the
adjusted difference in the mean per-patient costs between the CHIVST and SOC arm. In the base
case analysis, the ICER for offering the CHIVST was I$163.77, 95% CI [151.57, 175.37],
meaning that offering truck drivers the CHI
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VST costs I$163 per additional HIV test uptake compared to the SOC.

Uncertainty
Our findings were robust to variations in economic costs and effectiveness of CHIVST. The cost
of cell phone service and HIV self-testing kit were the key cost drivers and had the largest
impact on the ICER (Figure 1), although the upper bound of the ICERs for both sensitivity
analyses fell well below traditional willingness-to-pay thresholds. I examined the potential
impact the HIV self-testing kit price reduction to US $2, based on the Bill and Melinda Gates
Foundation agreement with manufactures and low-income countries.68 With the reduced price,
CHIVST was cost-effective at a much lower willingness-to-pay value (I$ 119 vs I$ 163).
Offering the CHIVST was still cost-effective in both the best- and worst-case scenarios (results
reported in the supplementary material).

CHIVST increases both costs and effectiveness but is cost-effective at low willingness-to-pay
thresholds. The joint distribution shows (Figure 2) that all the data points on the costeffectiveness plane are in the northeastern quadrant. This indicates that offering the CHIVST
increases both costs and HIV testing uptake and that there is less uncertainty in the cost per
additional HIV test performed since all the data points are clustered in the same quadrant. The
probability of CHIVST being cost-effective compared to the SOC is almost equal to 1 when the
willingness-to-pay value is greater than I$ 250 (Figure 2), which is much lower than even the
minimum willingness-to-pay threshold considered of I$3,258 (1xGDP per capita).

Discussion
HIV status awareness remains low, particularly in high-risk sub-populations in sub-Saharan
Africa, and improving HIV test uptake may require efficient, innovative, and targeted strategies.
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I examined the cost-effectiveness of offering the CHIVST to truck drivers at a roadside clinic in
Kenya compared to the SOC. I found CHIVST was effective—increasing the probability of HIV
testing uptake by 23%—and cost-effective when the decision maker is willing to pay I$163 per
additional truck driver tested for HIV per year.

CHIVST costs more, with the mean cost of an HIV test uptake more than four times higher, but
it is cost-effective, compared to the SOC. Although participants in the trial did not pay for the
testing kits, cost remains one of the main barriers to accessing healthcare services, including HIV
testing, and truck drivers consider cost as the strongest factor for the choice of HIV test. 69
However, CHIVST was cost-effective compared to the SOC at willingness-to-pay of I$163 for
an additional HIV test uptake, which is substantially lower than the willingness-to-pay threshold
used for Kenya ($I9,774), suggesting that although CHIVST costs more, it has a higher health
benefit and offers good value for money. Our findings were robust to extreme scenarios when I
considered higher bounds of all costs, which are driven primarily by the cost of the cell phone
service and HIV self-test kit in the CHIVST arm. I also considered a scenario with a selfadministered oral HIV test kit costing US $2 based on Bill and Melinda Gates Foundation
agreement with manufactures and low- and middle-income countries,68 but it did not change the
policy conclusion.

This study provides a novel contribution to emerging broader literature on the effectiveness and
cost-effectiveness of HIV self-testing, which has largely focused on the overall population of
people living with HIV.45–47 While little has been done to examine the cost and costeffectiveness of HIV self-testing among truck drivers, previous work conducted a costing
analysis and found self-administered oral HIV testing per test costs more (double) than routine

21

facility-based testing (the standard of care),32 which is consistent with the current study.
However, previous work did not examine the cost-effectiveness, and costs were only estimated
from a provider perspective.32 To our knowledge, this is the first study to examine the costeffectiveness of offering the CHIVST compared to the SOC among truck drivers in this setting.
In Zimbabwe47 and Malawi,45 HIV self-testing in the general population was cost-effective
compared to the provider administered HIV testing. Similar to findings in this study, the cost of
HIV self-testing kit was higher compared to the provider-administered HIV testing kit and was
one of the key variables impacting the cost-effectiveness of HIV self-testing. In Zimbabwe, HIV
self-testing was cost-effective when efficacy was at least 20%,47 which is comparable to the
effectiveness (23%) of CHIVST. Only one study from sub-Saharan Africa included a high-risk
or hard-to-reach sub-population (female sex workers) and found HIV self-testing to be costeffective when targeting female sex workers and in settings with high prevalence of undiagnosed
HIV.46 Based on previous work, more than 80% of HIV-infected truck drivers were unaware of
their HIV status in some settings,5 suggesting a high likelihood of HIV self-testing being costeffective in this sub-population. Although our study findings are broadly comparable with the
HIV self-testing literature, they should be interpreted with caution since I examined the costeffectiveness of offering a choice of HIV self-testing in addition to the SOC test and not of
offering only HIV self-testing. A large proportion of truck drivers in the CHIVST arm still chose
the standard of care test, suggesting that some truck drivers may choose not to test if offered only
HIV self-testing. In addition, I considered a short time horizon (3 months) and different
effectiveness measure compared to previous work done in the overall population of PLWH that
used mathematical models and considered a 20-year time horizon and long-term measures of
effectiveness (e.g., DALYs).45–47
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Findings indicate that differentiated care—in this case, choice of self-administered oral HIV
testing for high-risk sub-populations—is an effective and cost-effective strategy to improve HIV
test uptake. In Eastern and Southern African, HIV testing uptake remains low despite healthcare
services being geographically and temporally convenient.34 For example, roadside wellness
centers, such as those run by North Star Alliance, offer a broad menu of healthcare services,
including HIV testing and treatment, close to truck stops where truck drivers, sex workers and
roadside community residents congregate and interact and at off hours when these groups are
more likely to have time to seek services, but test uptake is low.34 CHIVST provides a costeffective potential solution to some of the limitations (e.g., lack of flexibility and privacy) of the
SOC HIV testing offered at the roadside wellness clinics.70

Our results contribute to a substantial gap in knowledge on efficient strategies to improve HIV
status awareness among truck drivers and other high-risk or hard-to-reach sub-populations in the
sub-Saharan Africa, a region with more than half of the world’s HIV population. In Kenya and
Uganda, along the trans-African highway, sexual interaction between transport workers and
communities at truck stops was estimated to contribute up to 4,148 new HIV infections in a
year.38 International and local policy makers could implement efficient strategies such as
CHIVST that improves HIV testing uptake as one strategy to reduce onward HIV transmission
by diagnosing people early and engaging them in HIV care. HIV-positive individuals aware of
their HIV status are likely to have fewer sexual partners and to use condoms compared to those
unaware of their status,71 thus reducing onward HIV transmissions. But, despite the increase in
the number of countries (from 6 to 77 countries in 2015 and 2019, respectively) in support of
HIV self-testing policies, implementation and integration of HIV self-testing in national HIV
programs remains a challenge,41 with less than 37% (28/77) of the countries at the
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implementation stage.72 Findings from this study provide supporting evidence to guide policy
makers in their decision making and implementation of HIV self-testing, particularly in high-risk
sub-populations.

This study had some limitations to consider in its interpretation. First, I did not account for future
costs and health benefits beyond the intervention period (3 months). For example, cost of
antiretroviral drugs and health benefits such as disability-adjusted life years averted that account
for long-term health benefits for truck drivers who were diagnosed with HIV and initiated on
ART. Additionally, the effectiveness and incremental effectiveness were estimated using an
intermediate outcome (HIV testing uptake), which limits comparability with cost-effectiveness
studies in literature that used traditional measures (e.g., disability adjusted life years). Although
using a mathematical model with a longer time horizon would account for future consequences, a
trial-based cost-effectiveness analysis provides evidence to inform policy decisions which are
usually implemented on short term basis (e.g., 1 to 5 years). Second, CHIVST was offered in a
healthcare facility setting among truck drivers already seeking care, who may have different
healthcare utilization behaviors compared those not accessing the healthcare facility. However,
the intervention is likely to be more effective in the outside setting. Third, economic costs data
were derived from literature since I did not collect data on the exact costs incurred during the
trial. However, I conducted sensitivity analyses to account for uncertainty in cost estimates and
the findings were robust.

As countries aim to achieve UNAIDS targets with limited resources available, innovative, and
targeted cost-effective strategies are imperative, particularly for sub-populations at high risk of
acquiring and transmitting HIV. This study finds offering self-administered oral HIV testing as a
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testing choice at roadside wellness clinics in Kenya to be a highly efficient use of resources
compared to the SOC of offering provider-administered blood-based HIV testing only. Future
studies should examine the cost-effectiveness of self-administered HIV testing outside the clinic
setting among high-risk sub-populations and consider the long-term costs and health benefits of
HIV testing.
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Chapter III: Cost-effectiveness of Alternative HIV Testing Strategies
among Hard-to-Reach Populations in Eastern and Southern Africa
Introduction
HIV testing remains substantially low in populations that are hard-to-reach and at high-risk of
transmitting HIV.2,5,8–10 These populations that are difficult to interact or engage with due to their
unique behaviors and characteristics, and as result, are hard to reach and engage in care. 1 Low
HIV testing has downstream consequences for engagement in HIV care, new HIV infections 73
and may halt the global target of ending the HIV epidemic by 2030.20

Female sex workers (FSWs) and long-distance truck drivers (truck drivers), particularly in
Eastern and Southern Africa, have been hard-to-reach and are disproportionately impacted by
HIV, with prevalence more than five times that of the general population in some settings.2,5,7
Traditional facility-based HIV testing approaches may not to reach these populations because of
the unique barriers they face in accessing care.3,10 For example, truck drivers are highly mobile
due to their occupation and usual opening hours at healthcare facilities are unfavorable for
routine health care utilization.74,75 FSWs face various barriers including provider stigma and
discrimination, which may negatively impact their willingness to seek HIV prevention services
and care.76,77

Innovative strategies targeting high-risk and hard-to-reach populations have shown improved
uptake of HIV testing but require more resources21,22 and their cost-effectiveness remains
unknown, despite the urgent need for efficient allocation of limited HIV funds. Globally, HIV
funding has stagnated, and over the past decade, funding from high-income countries has
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declined by more than $1 billion and future funding remains uncertain.28 This increases the
burden on low-income countries to close the ongoing and increasing funding gap.78 To ensure
long-term sustainability of the HIV response programs, resources need to be allocated efficiently
by investing in cost-effective strategies. In this study, I examined the cost-effectiveness of
alternative HIV testing strategies among female sex workers and long-distance truck drivers in
Eastern and Southern Africa.

Methods
Overview
I used a Markov model to examine the cost-effectiveness of seven HIV testing strategies in a
hypothetical cohort of 30-year-old21,22 undiagnosed truck drivers and FSWs living with HIV. The
primary outcomes included economic costs, life expectancy, disability-adjusted life years
(DALYs) lost and incremental cost-effectiveness ratios (ICERs). The analysis was conducted
from the societal perspective over a lifetime time horizon, with future economic costs and
DALYs discounted at 3%.60 Economic costs were valued in US dollars ($) and inflation-adjusted
to 2017 currency year. The relative performance of the HIV testing strategies was assessed using
the ICER (2017 $/DALYs averted), and the cost-effectiveness determined based on the
willingness to pay threshold equivalent to 3xGDP per capita for Kenya in 2017 ($4,710),60
although lower thresholds were also assessed to account for differences in affordability and
willingness to pay across settings.61–64,79 I assessed uncertainty in parameter inputs using
deterministic sensitivity analysis.
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Strategies
Seven strategies were examined (Table 2): i) No testing; ii) voluntary counseling and testing
(VCT);29 iii) provider-initiated and -administered testing and counseling (PITC);21 delivery of:
iv) self-testing kits, v) self-testing coupons, and vi) HIV testing referral cards in the community
using peer-educators;22 and vii) offering a choice of self-testing at the health facility in addition
to provider-initiated and -administered testing.21 Strategies were classified (community, facility
and combination of both facility and community) based on the setting of the initial contact with
target population and setting for HIV test uptake. Community-based strategies had higher costs,
probability of reaching the target population and HIV test uptake compared to facility-based
strategies.

Model Structure
I used a Markov model with mutually exclusive health states—a single state of health where one
event occurs per time period—but with probabilities that collectively sum up to 1. Statetransition probabilities are exponentially distributed (constant) and conditional on current but not
previous health states.80 The model has 24 health states defined by HIV disease progression and
engagement in clinical HIV care (Figure 3).81 The clinical stages of HIV disease progression
were defined as follows: Asymptomatic Early (corresponding with CD4 count >500 cells/μL);
Asymptomatic Late (corresponding with CD4 count >350 - 500 cells/μL); Symptomatic (CD4
count >200-350 cells/μL); and AIDS (CD4 count <200 cells/μL)). Disease stages defined based
on CD4 stratification is consistent with current mathematical modeling literature and enables
estimation of benefits and costs for diagnosis, linkage and ART initiation at early vs later stages
of the disease.82,83 The model did not include health states reflecting viral suppression due to data
limitations among people living with HIV in these settings. Further, the differences in health
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benefits across strategies attributed to viral suppression in the long run would be minimal after
discounting. I assumed that individuals who were consistently on ART (first or second line)
achieved viral suppression. Engagement in HIV care was characterized as undiagnosed,
diagnosed, linked to care, on first line ART, on second-line ART, lost from care, and death.
Although current guidelines recommend test and treat, evidence shows delays in linkage and
ART initiation in this setting.84

HIV diagnosis cascade (Figure 4) implemented in this study followed the HIV testing algorithm
in Kenya.85 The cohort undergoing HIV testing received an initial test and if the test was a
reactive test, a confirmatory test was performed, with a tiebreaker test used when the initial test
was reactive, but the confirmatory test had a negative result. Figure 4 shows pathways with
fraction of the cohort moving from undiagnosed to diagnosed health states. The sensitivity of the
initial HIV test was strategy specific, but the confirmatory test and tie-breaker test was the same
across all strategies. Strategies (Kit Delivery, Coupon Delivery and HIVST Choice) that offered
the oral self-administered test used the Oral Sure OraQuick test, with sensitivity (95%
confidence interval) of 92% (66.0 – 99.0).86,87 Strategies (Referral card, HIVST Choice, PITC,
VCT) that offered the blood-based provider-administered test used KHB colloidal Gold test,
sensitivity (95% CI) = 100.0% (97.4 – 100.0).85 Sensitivity of the confirmatory (First Response
1-2.0) and tiebreaker (Uni-Gold) test were 100.0% (97.4 – 100.0) and 96.4% (91.8 – 98.8),85
respectively. Consistent with the current HIV care guidelines in Kenya, those diagnosed with
HIV were linked to care and initiated on treatment irrespective of the disease stage. 88 Death
could occur in all health states due HIV- or non-HIV-related causes with variations in the
probability of death based on disease stage, engagement in HIV care89 and background
mortality.90 The model (Figure 3) was implemented in TreeAge Pro software version 2021.
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I made the following key assumptions: 1) I assumed FSWs and truck drivers older than 49 years
were not considered part of the high-risk and hard-to-reach populations and were comparable to
the overall population of people living with HIV (PLWH). Based on previous research, a
significant majority (>85%) of truck drivers and FSWs are below 50 years and I assumed they
change occupations.8,42,70,91 2) HIV testing strategies that used peer-educators reached all the
targeted population since they work in smaller groups and are likely to trace, follow-up and gain
trust of their peers.92 3) All truck drivers and FSWs that got a reactive initial HIV test and a
confirmatory test were linked to care and initiated treatment.

Parameter inputs
Data for parameter inputs (Table 3): HIV test uptake, disease progression, engagement in HIV
care and death came from published and grey literature, and were converted to monthly
probabilities to reflect the model cycle length.93 The initial distribution of 30 year-old,
undiagnosed individuals living with HIV came from a cohort study of newly diagnosed HIV
individuals in Kenya.94 I varied this distribution in sensitivity analysis to reflect limited data on
CD4 cell count distribution among truck drivers and FSWs living with HIV in sub-Saharan
Africa.

HIV test uptake data came from two randomized controlled trials (RCT) conducted in Uganda
and Kenya among FSWs (Intervention = 610; Control = 316)95 and truck drivers (Intervention =
150; Control=155),21 respectively, and two studies with evidence on HIV test uptake among
truck drivers and FSWs for the VCT strategy (standard of care).21,96 HIV test uptake varied based
on setting, sex, age, HIV disease stage and, with community-based (vs facility-based) strategies
reaching more people97,98 and women testing more than men except in older adults above 50
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years.99 Further, those at AIDS stage were more likely to test since they tend to be sicker
compared to those in non-AIDS stage.100

After the initial reactive test, a confirmatory test was required before linkage to HIV care and
ART initiation. I assumed perfect (100%) receipt of a confirmatory test in facility-based testing
and 90% for community-based testing with peer educators.92,101 Data for timely (within 30 days
of HIV diagnosis) linkage to care and ART initiation came from a longitudinal study on “test and
treat” in sub-Saharan Africa.102 Data for loss-to-follow-up (LTFU) came from a retrospective
study among FSWs in Rwanda.14 HIV natural history data came from a community-based HIV
testing study in South Africa, which estimated disease progression by fitting data to a pooledanalysis of observational cohort studies in Africa.83 Mortality data for PLWH who were not on
ART came from a longitudinal study in South Africa.89 I assumed mortality reduces by 58%
among PLWH and on ART.103 I accounted for age and sex specific background mortality using
the World Health Organization (WHO) life tables.90

Disability weights, which represented the total disease burden, were assigned to each health state
to project disability-adjusted life-years (DALYs) per strategy.104 The sum of weights over the
analytic time horizon reflected the total strategy specific DALYs lost. Monthly disability weights
came from Eaton et al.,105 derived from the global disease burden study.106 Disability weights
varied based on disease stage (asymptomatic, symptomatic and AIDS) and ART status (On ART
and Not on ART). I assigned equal disability weights for all ART health states, irrespective of
the disease stage, which is also consistent with other mathematical modeling studies.107–109
Future DALYs were discounted at 3% per annum.
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Costs
Economic costs associated with each HIV testing strategy, linkage to care and ART drugs came
from published and grey literature. Costs were valued US dollars for comparability with prior
studies and inflation-adjusted to 2017 currency year using the GDP deflator.60 Future costs were
discounted at an annual rate of 3%.60 HIV testing costs varied by strategy based on the setting
(community-based vs healthcare facility-based), medical supplies (blood-based test vs oral selftest), personnel, and patient costs (patient time and transport to healthcare facility). Facilitybased strategies required patients to visit the healthcare facility and incurred transportation costs
and more time associated with the HIV testing process. Community-based strategies reduced
patient costs but incurred more costs to reach patients in the communities. Costs considered
included medical (HIV test kits, ART drugs and medical supplies), personnel (salaries for the
nurse, healthcare facility management and peer educators), capital (healthcare facility site),
overhead, patient time and transport to the healthcare facility. Cost data for HIV self-test kits,
personnel, overhead, capital, training and medical supplies costs came from the trial55 and a
costing analysis conducted among truck drivers in Kenya.32 Costs for peer-educators came from
the RCT in Uganda that used peer-educators to distribute HIV self-testing kit and coupons to
FSWs.22 Costs associated with delivery of HIV care among patients on Pre-ART and ART came
from the ministry of health report on the cost of comprehensive HIV treatment in Kenya. 110 The
cost of ART drugs (first line - TDF+3TC (FTC)+EFV; second line AZT+3TC+ATV/r)111 came
from the Médecins Sans Frontieres report on ART prices in low and middle income countries. 112

Cost-effectiveness analysis
The total cost and DALYs lost per HIV testing strategy over the time horizon were used to
calculate the incremental cost, incremental effectiveness (DALYs averted) and the incremental
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effectiveness ratio (ICER). The ICER represents the cost of averting a DALY lost for a given
HIV testing strategy compared to the next least costly strategy. HIV testing strategies that cost
more but have less health benefits (DALYs averted) compared to the next best alternative are
strongly dominated (represented as “s_domintaed”). Those with lower cost and lower health
benefits compared to the next most costly strategy are considered weakly dominated (represented
as “w_dominated”). Performance of strategies was evaluated by comparing the ICER with the
willingness pay threshold (3xGDP per capita for Kenya in 2017),60 where a strategy is
considered to be cost-effective when the ICER is less than the willingness to pay threshold. The
threshold represents the willingness to pay value for the additional health benefit gained from a
strategy compared to other competing interests. I considered lower thresholds (1-3xGDP per
capita) to account for differences in affordability across settings 61–64,79 and examine the
robustness of our findings considering at lower willingness to pay thresholds. Further, since
many factors (e.g., data quality, the comparator, and sub-groups of the target population) can
impact the cost-effectiveness of an intervention, using a fixed WTP threshold as the only criteria
to guide decision-making may lead to a wrong decision.61 There is an ongoing debate in
literature about the true WTP threshold to determine the cost-effectiveness of a strategy, partly
due to the multiple factors that inform decision making. By considering different WTP
thresholds, I account for the uncertainty in the WTP threshold.

Sensitivity analysis
I performed deterministic sensitivity analysis to identify parameter inputs that impact the ICER
including the initial distribution given limited data on CD4 in undiagnosed high-risk populations
in this setting. Given that our target population is hard to reach, I examined the threshold under
which the probability of reaching the targeted population may impact the base case findings. I
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first assumed equal probability of reaching the targeted in both community- and facility-based
strategies and then examined the threshold for the probability of reaching the targeted population
where the community-based strategy may not be cost-effective. In the base case analysis, I
assumed that truck drivers and FSWs transition into other occupations by age 50 and were
considered part of PLHW in non-high-risk populations. Therefore, I assumed that the probability
of reaching the targeted population, HIV test uptake and LTFU varied between age <50 and ≥50
years. I relaxed this assumption and considered truck drivers and FSWs to remain as high-risk
sub-populations for the entire time horizon.

Model validation
The model was validated by comparing the life expectancy at 30 years for truck drivers and
FSWs living with HIV and on ART to overall population of PLWH in Rwanda on ART.113 Life
expectancy for truck drivers and FSWs in a given CD4 strata was estimated by assuming all
(100%) the initial cohort in that CD4 strata and projecting life years over the lifetime horizon.
The life expectancy increased based on the CD4 strata at the time of HIV diagnosis with truck
drivers and FSWs diagnosed at AIDS stage and initiated on treatment having a life expectancy of
nearly 20 years compared to 29 years among those diagnosed at asymptomatic early stage. Life
expectancy (Figure 5) estimated in the model was comparable to data from the literature except
for the cohort that were diagnosed with CD4>500 which had a lower life expectancy than that
reported in the literature. However, this could be a result of high LTFU in hard-to-reach
populations and delays in linking to care and initiating treatment. The average life expectancy at
30 years in the model for those diagnosed with CD4>500, CD4 >350 – 500, CD4 >200-350, and
CD4 <200 was 27.9, 27.1, 25.0 and 19.7, respectively which was comparable with that (30.1,
27.3, 25.9 and 19.06) of people living with HIV in the overall population
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Results
Base case analysis
In the base case analysis (Table 4 & 5), among both FSWs and truck drivers, the Kit delivery
strategy was cost-effective and had the highest cost and life expectancy at 30 years and lowest
DALYs lost. The “No testing” strategy had the lowest cost and life expectancy at 30 years and
highest DALYs lost. For undiscounted outcomes, total costs ranged from $1,700 to $10,100 and
$1,700 to $7,500 in the “No testing” and “Kit delivery” strategies among FSWs and truck
drivers, respectively. More DALYs were lost in the “No testing” strategy (45.36 and 45.6)
compared to the “Kit delivery” strategy (29.31 and 33.78) among FSWs and truck drivers,
respectively. Findings were consistent for the discounted outcomes. Costs ranged from $1,400 to
$6,100 and $1,400 to $4,951; and DALYs lost from 21.93 to 12.70, and from 22.11 and 14.77
among FSWs and truck drivers, respectively. The “Kit delivery” strategy was cost-effective with
an ICER of $520 and $480 among FSWs and Truck Drivers, respectively. For undiscounted
estimates, all strategies were dominated by the “Kit delivery” strategy in FSWs and truck drivers.
However discounted estimates, among FSWs, although the ICERs for the provider-initiated
testing ($500) and HIVST Choice ($510) strategies were lower than the WTP and comparable to
the ICER for the Kit delivery strategy, these strategies had more DALYs lost compared to the
Kit delivery strategy.

Sensitivity analysis
Base case results were mainly sensitive to the cost of ART although policy conclusions did not
change. Results of the one-way sensitivity analysis were reported in tornado diagrams, Figure 6
and 7 for FSWs and truck drivers, respectively. Given that our target population was hard to
reach, I assessed how the probability of being reached would impact the base case results. When
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I assumed equal reach between facility- and community-based strategies, the Kit delivery
strategy was still cost-effective (ICER = $498/DALY averted) among truck drivers but among
FSWs, the HIVST choice strategy was cost-effective (ICER = $516/DALY averted). In addition,
I found that when the probability of reach is below 75%, the kit delivery strategy ceases to be
cost-effective among FSWs but not truck drivers. Results were also sensitive to the probability of
disclosing test results and seeking a confirmatory test. I found that when the probability of
discloser is less than 60%, the Referral card strategy is cost-effective (ICER = $520/DALY
averted) among FSWs but not in truck drivers. When I considered truck drivers and FSWs to
remain as high-risk for the entire time horizon, base case findings didn’t change substantially,
with HIVST kit delivery remaining cost-effective among both truck drivers and FSWs.

Discussion
HIV testing and counseling remains substantially low in high-risk and hard-to-reach populations,
but little is known about cost-effective strategies to improve HIV test uptake in these
populations, particularly in Eastern and Southern Africa. I developed a Markov model to
examine the cost-effectiveness of six alternative HIV testing strategies in hard-to-reach
populations (truck drivers and FSWs). I found that the delivery of HIVST kits to the targeted
population in the community using peer-educators is a cost-effective strategy in both truck
drivers and FSWs with an ICER of $480 and $520, respectively. The findings were largely
robust to parameter variations in sensitivity analysis but delivery of HIVST kits in the
community was not cost-effective among FSWs when the probability of reaching the
undiagnosed FWSs or disclosing test results was less than 75% and 60%, respectively.
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The findings were broadly consistent with the literature although limited evidence exists on costeffective HIV testing strategies among high-risk and hard-to-reach populations. Previous studies
evaluating the cost-effectiveness of HIV testing have largely focused on the general population,
and among high-risk populations, few have included FSWs but not truck drivers. Comparable to
this study findings, previous work has shown that community-based strategies, including
community-based HIV self-testing, were cost-effective compared to facility-based strategies,
particularly in high prevalence areas such Eastern and Southern Africa. For example, in Uganda
and South Africa, home-based testing was cost-effective compared to facility-based with an
ICER of $3.5 per patient tested114 and $2,960 per HIV infection averted,115 respectively. Homebased HIV testing was more cost-effective when targeting high HIV prevalence (32%) areas,
with linkage to care and ART initiation expanded to individuals with CD4 cell count >350.115
Although evidence is limited and emerging, HIVST seems to be cost-effective compared to
blood-based provider administered HIV testing. For example, community-based HIVST was
cost-effective when uptake of HIV testing increased by at least 20% with the cost of HIVST kit
less than $347 and when more individuals were diagnosed at early stages of the disease and
immediately enrolled on ART.45 One study that included FSWs as part of the sub-populations in
the model, found the community-based HIVST to be cost-effective when the prevalence of
undiagnosed FSWs was above 5.5% and the cost per patient equal to $5.61.46

Hard-to-reach and high-risk populations have high HIV prevalence and a substantial proportion
remain undiagnosed until late stages of the disease. With community-based HIV testing116–118
such as home-based HIV testing, more undiagnosed individuals may be reached. Home-based
VCT and mobile HIV testing have substantially higher (83% and 98%) HIV testing uptake
compared to facility-based approaches.119 Further, community-based approaches reach
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undiagnosed individuals at earlier stages of the disease, which can potentially avert new HIV
infections and reduce mobility and mortality through early linkage to care and initiation of ART.
But despite having high HIV test uptake, community-based approaches have low rates (15-35%)
of linkage to care120 although this can improved (97%) with facilitated linkage to care
programs.119 With facilitated linkage to care programs, the Delivery of HIVST kits at truck stops
may be cost-effective.

This is the first study to examine the cost-effectiveness of HIV testing strategies including HIV
self-testing and the use of peer-educators with a focus on both truck drivers and FSWs. There is
strong evidence supporting use of peer-educators to promote HIV prevention, particularly in
high-risk and hard-to-reach populations.92 I found the HIVST kit delivery strategy using peereducators cost-effective in both truck drivers and FSWs. Peer-educators usually operate in
smaller groups and are able to gain access and trust to populations that are hard to reach with the
usual standard of care practices. For example, among FSW, the kit delivery strategy overcomes
the limitation of provider stigma faced by FSWs when seeking health care services, particularly
in countries where sex work is illegal. Truck drivers are hard to reach due to the unique
characteristics of their occupation—highly mobile—that may impact utilization of routine health
care services. Using peer-educators may be a suitable strategy to reach those that do not routinely
visit the health facility. Previous work on truck drivers has shown that even when drivers are
aware of HIV testing services at the healthcare facility that is geographically accessible (e.g.,
roadside wellness clinic along the truck routes), they were not willing to visit to the health
facility.42 The HIVST kit delivery strategy may improve HIV testing uptake within this
population through delivery of kits at truck stops. Although community-based strategies such as
the HIVST kit delivery tend to have lower rates of linkage to care compared to facility-based
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strategies, using peer-educators may also improve linkage to care and ART initiation by
motivating those that test positive for HIV to seek medical care. The kit delivery strategy may
also be more attractive to payers since it has high rates of HIV test uptake and requires low
skilled labor as compared to provider-administered facility-based testing. But there is a potential
problem of high turnover which may negatively impact continuity of the strategy when
implemented and overall effectiveness and costs incurred in frequent hiring and training.

This study had several limitations: 1) I did not account for HIV prevalence, which impacts the
percentage of individuals diagnosed, total strategy costs and DALYs. When the HIV prevalence
is high, more individuals are identified, linked to care, and initiated on treatment increases the
costs for the strategy through antiretroviral drugs but lowers the DALYs. By not accounting for
HIV prevalence, I am unable to determine thresholds at which strategies are cost-effective based
on HIV prevalence in the cohort. However, prior evidence shows HIV testing strategies have
been consistently cost-effective even in low prevalence settings of less than 1%.46,121–123 Both
truck drivers and FSWs have relatively high HIV prevalence (>10%),2–7 thus, considering HIV
prevalence will not change the study’s overall policy conclusions. For example, in one study
HIV prevalence was varied from 0.01% to 20% and was found to be cost-effective in all cases.123
At 0.01% HIV prevalence, the incremental cost-effectiveness ratio was $451 per quality adjusted
life years gained, which is much lower than the GDP per-capita threshold for most of lowincome countries.124 In a community-based self-testing study, HIV testing was found to be costeffective with HIV prevalence of undiagnosed individuals at 3%.46 Given that HIV prevalence is
high among hard-to-reach populations,125 HIV testing strategies are likely to be cost-effective at
all levels of HIV prevalence. 2) Due to data limitations, I did not include viral suppression in the
model and assumed that all fractions of the cohort in ART health states achieved viral
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suppression. This assumption may have overestimated the benefits of ART by not accounting for
those that did not achieve viral suppression. Those on ART were assigned lower disability
weights and by including those that haven’t achieved viral suppression, I may have increased the
effectiveness of the strategy and the incremental effectiveness, and as a result, the ICER may be
lower than the true value leading to wrong decision making. However, the ICERs were
substantially lower (<$700) than the WTP threshold ($4700) and thus, we do not anticipate
would materially impact the final policy recommendation. 3) Some of the HIV testing strategies
were only implemented in one sub-population (e.g., FSWs) but I assumed the same level of
efficacy applies to both sub-populations (truck drivers and FSWs). For example, HIVST kit
delivery, coupon delivery and VCT referral card were implemented among FSWs although I
assumed similar effectiveness among truck drivers and the HIVST choice was only implemented
among truck drivers. Although both truck drivers and FSWs are hard-to-reach, the efficacy of
these strategies may vary given that HIV testing varies based on gender.

Low uptake of HIV testing, particularly for high-risk and hard-to-reach populations significantly
impacts achievement of country and global UNIADS targets. Using peer-educators to deliver
HIV self-testing kits in the community is a cost-effective strategy to improve HIV test uptake in
populations that are hard to reach and at high-risk of acquiring and transmitting HIV. Future
studies should account viral suppression and HIV prevalence.
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Chapter IV: Cost-Effectiveness of Alternative Strategies to Reduce
Loss to Follow-up after Antiretroviral Therapy Initiation among Female
Sex Workers in Eastern and Southern Africa
Introduction
Female sex workers (FSWs) living with HIV, particularly in Eastern and Southern Africa, are at
high risk of loss to follow up (LTFU) from antiretroviral therapy (ART) programs.126,127
However, little evidence exists on strategies to reduce LTFU and their cost-effectiveness.
Consistent ART is beneficial for reducing HIV-related morbidity and mortality,128 and
preventing onward HIV transmissions when people living with HIV (PLWH) achieve viral
suppression.129 PLWH are considered LTFU if they miss their last three consecutive visits to the
health facility and are not classified as either dead or transferred-out to another healthcare
facility.130

FSWs are disproportionately impacted by HIV with 30 times higher risk of acquiring HIV
compared to the general population.131 In addition, they are hard-to-reach and face unique
barriers that impact their engagement in care.27 For example, FSWs are unlikely to self-identify
as sex workers due to fear of societal violence and provider stigmatization, particularly in
countries where sex work is illegal,27 which impacts their willingness to seek routine care and
retention in HIV care for those living with HIV.27 In fact, among those in HIV care and on ART,
up to 53% are LTFU after initiation of ART within 36 months,11–18 compared to 14% reported
for the overall population of PLWH.19 Given that nearly 1 in 5 of new HIV infections in subSaharan Africa is attributed to FSWs,132 retaining them in care and on ART is critical for
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improving HIV-related morbidity and mortality among those living with HIV and preventing
onward HIV transmissions.

This study examined the cost-effectiveness of strategies to reduce LTFU among FSWs after
initiating ART. Studies conducted in overall population of PLWH suggest home ART
delivery,133 home ART delivery with nutrition supplement,134 tracing patients who miss
appointment plus transport reimbursement135 and offering free medical care for opportunistic
infections and lab tests136 are effective in reducing LTFU. In West Africa, offering free medical
care for opportunistic infections, transport reimbursement and breakfast137 for PLWH was costeffective with a baseline LTFU ≥18% and risk reduction ≥41%.137 However, evidence on costeffective LTFU strategies is limited, and none exists among FSWs or other high-risk and hardto-reach populations.

To contextualize the contribution of this study, I discuss the evidence on the cost-effectiveness of
LTFU strategies in the overall PLWH. Strategies to reduce LTFU have been shown to be costeffective when the percentage of people living with HIV and on ART that are LTFU from ART
programs was at least 12%.133,137,138 Community support programs such as delivery of ART in
the community and supporting adolescents to adhere to treatment in South Africa reduced LTFU
by 40% compared to the standard of care (no community-based support) and was costeffective.133 One study examined the cost-effectiveness of three hypothetical strategies: 1) Risk
Reduction (40%), lower likelihood of disengaging from care, 2) Outreach (60%), patients with
missed ART appointments are traced and re-linked to care, and 3) a combination of both Risk
Reduction and Outreach strategies.138 Compared to the standard of care (no intervention), a
combination of Risk Reduction and Outreach was a cost-effective with increase in life
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expectancy by 5.2 years, 2.4 Quality adjusted life years (QALYs) gained and an incremental
cost-effectiveness ratio of $4700/QALY gained.138 However, these strategies were hypothetical
and their efficacy has not been examined in a real world setting. In West Africa, four strategies
to reduce LTFU: 1) elimination of ART co-payments; 2) #1 plus treatment costs for
opportunistic infections; 3) #2 plus increased training for health workers; and 4) #3 plus
reimbursing transportation costs and providing breakfast for patients attending scheduled visits
were examined.137 With a baseline annual LTFU reduction of 40% (from 18% to 11%), and
efficacy range (10% to 75%), a given strategy was be cost-effective if it costs between US $22 $77 per person-year with efficacy of at least 12 - 41%, respectively.137 These studies provide
baseline for examining strategies in other populations such as FSWs at high risk of LTFU but
with limited evidence on strategies to prevent LDTU. Further, identifying efficient strategies to
reduce LTFU is critical for guiding resource allocation, particularly in the current climate with
constraints in international funding for HIV response programs.28

Methods
Overview
I used a Markov model to examine costs and disability-adjusted life years (DALYs) lost of six
LTFU strategies in a cohort of FSWs living with HIV and receiving ART. The analysis was
conducted from a payer perspective with future DALYs lost and costs discounted at 3%. 60 Each
health state was assigned a disability weight to reflect the disease burden. Costs were valued in
US dollars and inflation-adjusted to 2017 currency year. The primary outcomes were costs,
DALYs averted, and incremental cost-effectiveness ratios (ICERs). The ICER was used to assess
the relative performance of the strategies, with the cost-effectiveness of a given strategy
determined according to a threshold of 3x the GDP per capita for Kenya in 2017 ($4,710),60
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although lower thresholds were also assessed to account for differences in affordability and
willingness to pay across settings.61–64,79 Uncertainty in inputs was assessed using probabilistic
sensitivity analysis.

Strategies

Six alternative strategies (Table 6) were examined: 1) No intervention; 2) Home ART delivery
using community-health workers133; 3) Home ART delivery using community-health workers
plus monthly nutrition supplement134; 4) physical and phone-tracing of patients that miss an
appointment plus transport refund to the health facility135; 5) physical and phone-tracing with
free medical care for opportunistic infections136; 6) free medical care for opportunistic infections
with transport refund to the health facility and free breakfast.137

LTFU strategies came from studies conducted among the overall population of PLWH. I
assumed that the effectiveness of these interventions is comparable when implemented in a highrisk and hard-to-reach population such as FSWs. I justified this assumption using the case of
HIV pre-exposure prophylaxis (PrEP) since PrEP interventions implemented in both the general
population and hard-to-reach population have been similar and have shown comparable
effectiveness, with overlap in 95% confidence intervals implying effectiveness across the two
populations is not statistically different.

I relied on PrEP interventions, versus other interventions at other steps along the HIV care
continuum, to justify this assumption for the following reasons: 1) PrEP interventions
implemented in the general population are also routinely implemented among hard-to-reach
populations, which enables comparison of their efficacy or effectiveness. 2) There is no evidence
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that different PrEP interventions are implemented for the general population and hard-to-reach
populations. 3) PrEP interventions are implemented over a longer time period (>1 year), require
longer-term adherence and compliance to treatment, and report HIV incidence, which can be
used as a proxy measure for adherence and patient behavior outcomes. Adherence is a key factor
associated with the likelihood of LTFU among people living with HIV.139 4) There is no
evidence that different interventions are implemented for the general population and hard-toreach populations at some additional key steps along the HIV care continuum, including linkage
and retention in care. Indeed, no evidence exists for any intervention to promote linkage or
retention in care among hard-to-reach populations of people living with HIV. Importantly,
however, interventions to improve HIV testing uptake—for which there is variation in
implementation across populations10,22,140–143—were not considered. This is because, these
interventions are implemented for a relatively short period of time22,144 (compared to PrEP
interventions),145,146 potentially at discrete intervals, and may not adequately capture patient
behavior (e.g., visiting the clinic regularly for drug refills), in terms of adherence to a longer term
prescribed regimen, over a period of time.

I focused in particular on a particular aspect of PrEP: patient behavior. I relied on patient
behavior—defined here in terms of adherence to ART or PrEP continuously and over a longer
time horizon—to justify the assumption that LTFU reduction strategies are similarly effective
among hard-to-reach populations living with HIV and on ART and among the overall population
of PLWH since the behavior that results in PrEP adherence parallels similar behaviors required
to remain in HIV care. This parallel is particularly relevant in sub-Saharan Africa where people
diagnosed with HIV not only take daily medication but must visit the clinic more regularly
(monthly or every two months) for drug refills.147 When examining adherence to PrEP, I found
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comparable adherence to PrEP among hard-to-reach populations and the general population for a
given intervention. For example, adherence to PrEP among female sex workers in South Africa
ranged from 70% at nine months and 95% at eighteen months13 compared to HIV discordant
couples with average adherence of ≥85% within a similar time period,148 which is within the
range for adherence to PrEP in FSWs.13 Notably, there is precedent in the mathematical
modeling literature to assume that intervention efficacy is similar across different populations.
For example, Anderson et al. assumed the efficacy of PrEP to be identical not only across
different sub-populations, including FSWs, but also for the general population.149

While there are differences in the measures of central tendency for PrEP effectiveness among the
general population and hard-to-reach populations, PrEP interventions among the general
population report comparable effectiveness among hard-to-reach populations, suggesting that
they are not statistically different across the two populations. I drew from this evidence to
assume that LTFU interventions are as effective in hard-to-reach populations as in the general
population.

Model structure
I used the Markov model in paper 2 (Figure 8) of the dissertation but restricted the initial cohort
distribution to health states prior to first-line ART. The model projected lifetime economic costs
and DALYs lost associated with each strategy in a hypothetical cohort of FSWs on ART, with a
mean age of 30 years. Model health states represented HIV disease clinical stages based on CD4
cell count to account for differences in the probability of LFTU across CD4 cell count strata. 150–
152

On-ART disease progression (i.e., changes in CD4 count due to ART) is not modeled, given

evidence that LTFU is associated with baseline CD4 count at ART initiation; however, disease
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progression is modeled in the absence of ART, with differences in the probability of LTFU and
death according to disease progresion.153,154 The initial cohort was followed over a lifetime time
horizon with transitions and outcomes updating monthly to reflect the average frequency of visits
to the clinic for drug refills in Eastern and Southern African countries.155–157 To project lifetime
DALYs lost and economic costs, each health state was assigned a disability weight and monthly
cost with the sum of DALYs and costs over the analytic time horizon to reflect total strategyspecific DALYs lost and costs.104

Data
Data for parameter inputs (Table 7) came from the literature. The initial distribution of FSWs on
ART came from a cohort study of newly diagnosed HIV individuals in Kenya,94 although I
assessed other distributions in sensitivity analysis given the limited CD4 data in this setting. 158
Probabilities of disease progression and switching to second-line ART came from a prospective
study among PLWH in South Africa83 and a retrospective study on rates of switching to secondline ART in Uganda,159 respectively. Monthly disability weights came from Eaton et al.,105
derived from the global disease burden study.106 I assumed equivalent disability weights for
asymptomatic health states (not on ART). Similarly, all health states indicating patients on ART
have equal disability weights irrespective of CD4 cell count given the clinical benefits of ART,
comparable to other mathematical modeling studies.107–109

Data for LTFU came from a retrospective study that examined retention in care among FSWs on
ART in sub-Saharan Africa.14 Data for LTFU risk reduction came from different studies
conducted among PLWH and on ART in sub-Saharan Africa: 1) a retrospective study among
young adults on ART in South Africa who received community-based ART delivery133; 2) a
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prospective community-based support program in Rwanda which provided home ART delivery
with nutrition support for PLWH and on ART134; 3) a retrospective study among PLWH in
Eastern Africa who were LTFU and traced to reengage them in HIV care135; 4) a prospective
study among adults on ART who received free medical care for opportunistic infections and lab
tests with a primary care physician and case manager to monitor the patients’ health136; 5) a
mathematical modeling study that examined hypothetical strategies to reduce LTFU including
offering free ART plus medical care for opportunistic infections, transport refund and
breakfast.137

Costs
Economic costs associated with each strategy came from the literature and reflected a payer
perspective.60 Costs were valued and reported in US dollars ($) and adjusted for inflation to 2017
currency year using the GDP deflator.60 Costs varied based on the strategy including medical
(ART drugs, opportunistic infections drugs and laboratory costs); labor (salaries for healthcare
workers including community health care workers, non-clinical healthcare facility staff,
physician, and lab technician); capital (health facility and equipment), overhead costs and patient
transport refund. Data for ART drugs, labor, capital and overhead costs came from the Ministry
of Health costing analysis report for treating PLWH in Kenya.110 The cost of patient transport to
the health facility came from a costing analysis report of PLWH in Uganda.160 Costs associated
with community-based ART delivery including training, salaries, management, equipment and
overhead came from a retrospective study among young adults on ART in South Africa.133 The
cost for nutrition supplement was estimated at approximately a $1 per day.161
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Cost-effectiveness Analysis
Performance of alternative strategies to reduce LTFU was determined based on the willingness
to pay (WTP) threshold of 1-3xGDP per capita of Kenya in 2017.60 We used Kenya as a
representative country in Eastern and Southern Africa since it has a large number of truck
drivers, routes and truck stops where drivers engage with FSWs.162 The WTP threshold
represents a country’s willingness to pay for an additional health benefit, measured as DALYs
averted in this study. The GDP per-capita is used as a WTP threshold because the health benefit
gained from the intervention would increase an individual’s productivity which is measured by
an increase the GDP per-capita. While I use a 3xGDP per capita threshold, I take in account the
ongoing debate regarding the true threshold for evaluating cost-effectiveness. This debate centers
on a criticism that the 1-3xGDP per capita threshold is too high for resource-limited settings,
given other competing priorities.61–64,79 To attend to this concern, I also evaluated costeffectiveness using a more conservative threshold of 1x GDP per capita for Kenya. Although
multiple factors are considered in the decision-making process, the WTP threshold provides a
monetary value with which to compare alternative strategies. Strategies with higher costs and
lower health benefits than the next most costly alternative were considered “strongly
dominated;” strategies with a higher ICER than the next most costly non-dominated alternative
strategy were eliminated as “weakly dominated” because they provide less health benefit per
additional cost unit.

Sensitivity analysis
One-way, multi-way and probabilistic sensitivity analysis were used to assess uncertainty in
parameter inputs. In one-way sensitivity analysis I identified the main cost drivers of variation in
the ICER, with the results reported using a tornado diagram, which summarizes the range of
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ICERs due to variation in unit cost estimates. For multi-way sensitivity analysis, I considered
extreme values (lower and upper bound) of parameter inputs to examine the impact of
simultaneous variation of parameters given that in a real-world setting multiple values change
concurrently. I conducted a probabilistic sensitivity analysis to assess the impact of random
variation in parameter inputs on the cost-effectiveness of the strategies. I assumed a beta and
gamma distribution for probability and cost variables, respectively. The beta distribution bounds
probability between 0-1 and the gamma accounts for skewness of cost data.163 Ten thousand
Monte Carlo simulations were performed with values sampled randomly within the parameter
input range, with ICERs calculated for each simulation. Results from simulations were reported
using a cost-effectiveness acceptability curve.66,67 The acceptability curve summarizes the
probability a strategy is cost-effective at different WTP thresholds. I accounted for
misclassification of LTFU given prior evidence from sub-Saharan Africa suggests that some
patients recorded as LTFU had died or transferred to another clinic.19,130,164–166 I applied a
probability weight of 0.43, derived from 1 – proportion LTFU who die (0.208) – proportion
LTFU who self-transfer from site (0.359). These estimates were based on evidence among
patients in ART programs in sub-Saharan Africa that suggested 20.8% and 35.9% of patients
recorded as LTFU had died or self-transferred to another ART clinic.19 In the base case analysis I
assumed that all strategies are implemented over the cohort’s lifetime, which may not be the case
in the real-world setting since programs are implemented for shorter time periods such as 5 and
10 years. In particular, “ART delivery + nutrition supplement” was the most effective but costly
strategy with nutrition supplement contributing a larger (65%) percentage of the cost. In the
sensitivity analysis, I examined the cost-effectiveness of the strategies with nutrition supplement
only offered for 5 and 10 years. Further, since “ART delivery + nutrition supplement” was not
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cost-effective in the base case, I examined the cost of nutrition supplement at which the strategy
would be cost-effective if it is offered throughout the cohort’s lifetime.

Results
Base case analysis
In the base case analysis (Tables 8 and 9), ART delivery was cost-effective compared to
alternative LTFU strategies. Undiscounted costs ranged from $4,664 to $16,292 and DALYs lost
from 28.41 to 23.40 in “No Intervention” and “ART delivery + nutrition supplement”,
respectively; discounted estimates ranged from $2,994 to $10,022 and 11.52 to 9.27,
respectively. ART delivery was cost-effective compared to alternative strategies with an ICER of
$470 per DALY averted. ART delivery with nutrition supplement had lower DALYs lost (9.27)
but cost substantially more compared to the next best alternative, ART delivery ($10,022 vs
$5,173). This resulted in an ICER of $5,100 per DALY averted and was not cost-effective at a
willingness to pay threshold of $4,710.

Sensitivity analysis
In one-way sensitivity analysis (Figure 9), we compared the impact of individual parameters on
the cost-effectiveness of the “ART delivery” strategy compared to “No Intervention”. ART drugs
had the largest impact on ICER, in particular, second line ART, and the relative reduction in
LTFU by the ART delivery. However, regardless of the variation in the ICER, the study
conclusions did not change, ART delivery remained cost-effective compared to No intervention.
In the multi-way sensitivity analysis (Tables 10 and 11), the ART delivery + Nutrition
supplement strategy was cost-effective when lower bound costs were considered while the
“Medical care + Transport + Breakfast” strategy was cost-effective for the upper bound costs. I
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examined the impacted of adjustment for LTFU misclassification, but the findings (Table 12 and
13) remained consistent with the base case analysis—ART Delivery remained cost-effective
compared to the No Intervention strategy, with an ICER of $500 per DALY averted. When I
reduced the time frame when the nutrition supplements were offered to 5 and 10 years
(supplementary material, Tables S21 and S22), the “ART delivery + Nutrition” supplement was
cost-effective in 5 years (ICER = $4,300) but not in 10 years (ICER = $6,880).

Results for the probabilistic sensitivity analysis are shown in the cost-effectiveness acceptability
curve (Figure 10). The probability of cost-effectiveness of a given strategy (No Intervention,
ART Delivery and ART Delivery + Nutrition Supplement) varied based on the WTP threshold.
When the WTP was <$500, No Intervention had the highest probability of cost-effectiveness;
$500-$4,600 ART Delivery was more likely to be cost-effective; and >$460 the ART Delivery +
Nutrition Supplement had a higher probability of cost-effectiveness. In the cost-effectiveness
plane (Figure 11), majority of the data points for incremental costs and incremental effectiveness
fall eastern quadrants of the plane, indicating that ART delivery averted DALYs but may also be
cost-saving.

Discussion
I used a Markov model to estimate costs and DALYs averted by strategies aimed at reducing
LTFU among FSWs living with HIV and on ART in Eastern and Southern Africa. Home ART
delivery using community-health workers was cost-effective at a willingness to pay threshold of
$ 470 per DALY averted. I estimated 0.98 DALYs could be averted at an additional cost of $
466. Taking an example of Rwanda with approximately 12,278 FSWs, of which 6,237 (50.8%)
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are living with HIV, these per patient estimates would translate to 6,112 DALYs averted at an
additional cost of $2.9m.

LTFU remains a major public health problem that negatively impacts the success of ART
programs, particularly in low-income settings.126,167 Previous studies indicate that LTFU from
ART programs increases the risk of treatment failure, drug resistance, viral load rebound and
mortality.128,167,168 A number of factors can contribute to LTFU from ART programs including
stigma to visit an HIV clinic, failure to remember getting treatment, distance to the health
facility, lack of transport to the clinic and being too sick to visit the clinic.169 These factors are
enhanced particularly among vulnerable populations such as FSWs, leading to higher rates of
LTFU.11–18 For example, in Côte d’ivoire, 53% of 376 female and 38 male sex workers were
LTFU of within a follow-up period of 36 months.14 In South African FSWs, 30% were LTFU
within 12 months, which is higher than what is reported (8.5%) in general population considering
the same time period.13

Strategies to reduce LTFU among FSWs living with HIV may cost more than in the overall HIV
population. Previous studies have shown that ART programs that work with members of the
community to follow up with patients to support them in adherence to treatment, report improved
retention in HIV care,170 but no study has examined the cost-effectiveness of this strategy. In this
study, I found ART delivery in the community was cost-effective in reducing LTFU suggesting
that reaching to patients in areas where they live and delivering ART drugs could be an efficient
way of retaining them on HIV treatment. Using peer-educators may be suitable for reach the
FSWs since some may not be easily identified by community health workers in the general
population and this may require me resources. A substantially body of literature has shown
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tracing (at home or by phone) patients that miss appointments at the clinic effective in reducing
LTFU171 however, I didn’t find tracing cost-effective in this study. This may potentially result
from higher costs of tracing a hard-to-reach population such as female sex workers. The costs of
tracing FSWs may be higher given that majority are less likely to disclose their physical address
for tracing, particularly in countries where sex work is illegal.

ART delivery + nutrition supplement (nutrition offered over a lifetime period) was the most
effective strategy but not cost-effective at a willingness to pay threshold of 3xGPD per capita of
Kenya ($4,710). Previous work has shown that the nutrition supplement may improve adherence
to treatment, retention in HIV care and reduce the mortality rate among patients on HIV
treatment since ART drugs affect their metabolism and good nutrition is vital is reducing the side
effects of the drugs.172 In this study, if the reduction in mortality rate was considered, the ART
delivery + nutrition supplement strategy may have been more effective with lower total number
of DALYs lost over the time horizon and potentially be cost-effective. Previous work found that
nutrition supplement was cost-effective when targeting HIV patients who start ART with low
body mass index and mulnarished.173 In sensitivity analysis, I found that offering nutrition
supplement for 5 years and reducing the amount of money from $30 to $15 per month would
result in ART delivery with nutrition supplement being cost-effective. This suggests that
nutrition supplement is a potentially cost-effective intervention when offered for a shorter time
period and targeting patients with food insecurity. Although nutrition supplement may be
effective in reducing LTFU and improving overall health of PLWH, there may be potential
unintended consequences such as FSWs getting HIV so that they can benefit from the nutrition
program.174
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The findings are novel yet comparable to the limited evidence on cost-effectiveness of LTFU
strategies in the overall population of PLWH.133,137,138 In South Africa, a community-based ART
support program for adolescents living with HIV was implemented for 2 years and reduced
LTFU by 40% compared to the standard of care (no community-based support) and was costeffective with an incremental cost-effectiveness ratio of US $600 per averted patient LTFU.133
Adolescents also require targets strategies since to engage in care and the findings133 support this
study conclusion that delivering ART in the communities is a cost-effective approach. In côte
d’ivoire, an intervention that offered free ART drugs, treatment costs for opportunistic
infections, increased training for health workers, reimbursing transportation costs and provided
breakfast for patients attending scheduled visits was found to be cost-effective in reducing LTFU
when costs ranged between $22 and $77 per person-year with efficacy of at least 12% to 41%.137
Although I did not examine this identical strategy, offering free medical care, transport
reimbursement and breakfast was not a cost-effective strategy compared to alternative strategies.

This study has several limitations. First, strategies to reduce LTFU that were examined in this
study came from previous work done in PLWH on ART in the overall HIV population, which is
not representative of a hard-to-reach population. However, despite the differences in study
populations, these strategies can be applied to hard-to-reach populations given that similar
strategies have been implemented in both hard-to-reach and overall HIV population to improve
adherence to PrEP and the effectiveness of those strategies was comparable. Second, this study
focuses on FSWs in the Eastern and Southern Africa region, but model parameters were largely
derived from Kenya, which I use as a case study country. Although Kenya is a good
representative of countries in this setting, estimates may not be generalizable to countries such as
South Africa where the cost of living and income classification is higher. Nevertheless, the
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findings make contribution to this topic and population that is under studied. Third, potential
benefits of nutrition supplement were not accounted for such as reduction in mortality rate which
could have increase the effectiveness of the ART delivery + nutrition supplement strategy and
potentially the cost-effectiveness. Finally, viral suppression was not included in the model due to
limitations of data to inform parameter inputs. Thus, I assumed that all patients on ART achieved
viral suppression. This assumption may have overestimated the benefits of ART and
underestimated the cost-effectiveness thresholds of the strategies. Although we found ART
delivery cost-effective at a low WTP threshold, results need to be interpreted with caution due to
potential overestimation of the effectiveness of the strategy from this assumption.

To achieve the global goal of ending the HIV epidemic, its critical to reach all PLWH, link, and
retain them on ART. Hard-to-reach populations including FSWs remain disproportionately
impacted by HIV with high rates of LTFU from ART programs. This study found that delivering
ART drugs to FSWs in their homes, places that they frequent, or community centers is a costeffective strategy to reduce LTFU among FSWs in ART programs in Eastern and Southern
Africa. Despite the lack of RCTs or observations studies examining the effectiveness of LTFU
strategies in FSWs or similar hard-to-reach populations, these findings provide insights on
efficient interventions to be considered by policy makers.
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Tables and Figures
Paper one
Table 1: Mean costs per patient, by cost component and trial arm, reported in 2017 I$
Cost component
CHIVST (Intervention)*
SOC (Control)†
PMean
95% CI
Mean
95% CI
value‡
HIV test Kit
10.12
[8.85 – 11.38]
0.00§
[0.00 – 0.00] <0.001
Medical Supplies
0.25
[0.22 – 0.27]
0.30
[0.27 – 0.33] <0.001
Labor
Nurse
2.37
[2.22 – 2.53]
1.64
[1.47 – 1.80] <0.001
Health facility staff 0.92
[0.86 – 0.99]
0.79
[0.71 – 0.87]
0.037
Training
0.08
[0.07 – 0.08]
0.00
[0.00 – 0.00] <0.001
Capital costs
Health facility
1.44
[1.34 – 1.54]
1.24
[1.11 – 1.37]
0.037
Equipment
2.18
[2.04 – 2.31]
0.00
[0.00 – 0.00] <0.001
Overhead
3.59
[3.35 – 3.83]
3.06
[2.75 – 3.37]
0.037
Cell phone service
12.03
[11.28 – 12.79]
0.00
[0.00 – 0.00] <0.001
Patient time
2.67
[2.45 – 2.79]
1.81
[1.63 – 1.99] <0.001
Cost per patient
35.59
[33.08 – 38.09]
8.84
[7.96 – 9.73] <0.001
Abbreviations: CHIVST=Choice of Self-Administered Oral HIV Testing; SOC = Standard of
care
* Participants were offered the choice to test for HIV using 1) the provider-administered HIV
testing or 2) self-administered oral HIV-testing under the supervision of a provider. If the truck
driver declined the two options, they were offered a third option; 3) self-administered oral HIVtesting outside the clinic (at home) without supervision of a provider.
† Participants were offered on the provider-administered HIV testing.
‡ The p-values are from the Wilcoxon rank sum test for differences in median costs by trial arm.
§ The cost of the SOC HIV test kit was I$0.00 because SOC kits were provided by the Kenyan
Ministry of Health at the clinic. However, I consider a scenario where the kits are not subsidized
by alternative sources in sensitivity analysis.
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Figure 1: One-way sensitivity analysis of unit costs
Base case ICER = I$163
Cell phone service

I$6.8

HIV self-test kit
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I$0.0

Patient time
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Health facility
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Figure 1 shows the incremental cost-effectiveness ratios (ICERs) corresponding to variations in
cost variables based on upper and lower bound values. The x-axis shows the ICER and y-axis the
cost variables considered in the study. The vertical line indicates the ICER (I$163) when costs
are considered at base line values. The costs of cell phone service and of the HIV self-testing kit
were the key drivers of costs and had the largest impact on the ICER followed by equipment
(cell phones), and economic cost of the SOC HIV test kit and patient time spent at the clinic for
the HIV testing process. Other cost variables have little impact on the ICER.
Figure 2, Panel A shows the joint distribution of the difference in cost (y-axis) and the difference
in risk of HIV testing uptake (x-axis) across trial arms from 1500 bootstrap samples. All the data
points on the cost-effectiveness plane are in the northeastern quadrant. This implies that offering
the CHIVST increases both costs and risk of HIV testing uptake and there is less uncertainty in
the cost per additional per HIV test performed since all the data points are clustered in the same
quadrant. Panel B shows the probability (y-axis) of CHIVST being cost-effective compared to
the SOC is almost equal to 1 when the willingness to pay value (x-axis) is greater than I$ 250.
The willingness-to-pay of I$ 250 is much lower than to the cost-effectiveness threshold of I$
9,774 (3xGDP per capita of Kenya in 2017), which shows that CHIVST is cost-effective
compared to the SOC even at very low willingness to pay thresholds. The black dot indicates the
base case willingness to pay (I$ 163) with the probability of cost-effectiveness at 0.5.
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Difference in cost (I$) per HIV test
between CHIVST and SOC

Figure 2: Joint distribution of difference in cost and effect, and the cost-effectiveness
acceptability curve
Panel A
28

27

26

Base case ICER (I$ 163)
25

24
0.13

0.14

0.15

0.16

0.17

0.18

0.19

Difference in risk of HIV testing uptake between CHIVST arm and SOC arm

Panel B

Probability of cost-effectiveness

1

0.75

0.5

0.25

Base case ICER (I$ 163)

0
100

150

200

250

Willingness to pay (I$) for additional HIV test
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Paper two
Table 2: HIV testing strategies with associated probability of reaching the target population, test-uptake, and cost per HIV test
Truck Drivers
Female Sex Workers
Category*
Strategy†
Cost ($ 2017)
Reach‡
Test uptake
Reach‡
Test uptake
Source
No testing
—
—
—
—
—
VCT

0.037

0.022

0.063

0.042

$ 6.77

29,32,56

PITC

0.037

0.103

0.063

0.175

$ 6.77

21,32,56

Community

Kit Delivery

0.319

0.198

0.319

0.198

$ 18.73

22,32,56,95

Combination

Coupon Delivery 0.319

0.040

0.319

0.115

$ 20.87

22,32,56,95

Referral card

0.319

0.035

0.319

0.093

$ 14.74

22,32,56,95

HIVST Choice

0.037

0.158

0.063

0.221

$ 13.11

21,32,56

Facility

Abbreviations: HIVST=HIV self-testing; VCT=Voluntary Counseling and Testing; PITC=Provider-initiated counseling and testing
*Strategies are classified based on the setting where the target population was reached and HIV testing. The combination category includes both the
health facility and the community setting.
†Strategies are defined as follow: 1) No Testing – I assumed that there is no HIV testing and all FSWs and Truck Drivers living with HIV remained
undiagnosed. 2) VCT – FSWs and Truck Drivers voluntarily visit the clinic and request an HIV test which is blood-based and provider-administered. 3)
PITC – A health provider at the health facility initiates the discussion with the patient to have an HIV test and when the patient agrees the provider
administers the blood-based HIV test. 4) Kit Delivery – HIV self-testing kits are delivered in communities to FSWs and Truck Drivers by peer-educators.
5) Coupon Delivery – HIV self-testing coupons are delivered in the communities to FSWs and Truck Drivers by peer-educators to exchange for a free-ofcharge HIV self-test kit at the health facility. 6) – Referral cards are delivered in the community by peer-educators to exchange for a free-of-charge
provider-administered blood-based HIV test. 7) HIVST Choice – FSWs and Truck Drivers who visit the clinic to seek care are offered a choice of
provider-administered blood-based rapid test OR oral HIV self-testing at the clinic OR, if either testing refused, oral HIV self-testing at home.
‡Reach is defined as the probability of getting in contact with the Truck Drivers and FSWs living with HIV and hard-to-reach.
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Table 3: Monthly Parameter Inputs
Baseline (range), [95% CI]
Truck drivers
Female sex workers

Parameter*
Initial distribution (%)

Source
94

Asymptomatic Early
Asymptomatic Late
Symptomatic
AIDS

28.8
19.6
19.7
31.9

Asymptomatic Late
Symptomatic
AIDS

0.013 (0.007 – 0.020)
0.029 (0.014 – 0.043)
0.023 (0.012 – 0.035)

Disease progression

Reaching undiagnosed individuals
30-49 years: Non-AIDS stage

30-49 years: AIDS stage

74,98,175,176

Community-based†
Facility-based‡

0.088 (0.045 – 0.129)
0.037 (0.018 – 0.054)

0.088 (0.045 – 0.129)
0.063 (0.032 – 0.093)

Community-based†
Facility-based‡

0.129 (0.067 – 0.188)
0.054 (0.028 – 0.080)

0.129 (0.067 – 0.188)
0.093 (0.047 – 0.135)

0.319 (0.175 – 0.438)
0.438 (0.250 – 0.578)

0.319 (0.175 – 0.438)
0.438 (0.250 – 0.578)

50+ years: Non-AIDS stage
50+ years: AIDS stage
HIV Testing
30-49 years: Non-AIDS stage

30-49 years: AIDS stage

83

21,22,29,91,177–180

HIVST Kit Delivery
HIVST Coupon Delivery
VCT Referral card
HIVST Choice
PITC
VCT

0.198 (0.104 – 0.282)
0.040 (0.020 – 0.059)
0.035 (0.017 – 0.052)
0.158 (0.082 – 0.227)
0.103 (0.053 – 0.151)
0.042 (0.021 – 0.063)

0.198 (0.104 – 0.282)
0.115 (0.059 – 0.167)
0.093 (0.047 – 0.136)
0.221 (0.117 – 0.312)
0.175 (0.091 – 0.250)
0.022 (0.011 – 0.033)

HIVST Kit Delivery
HIVST Coupon Delivery
VCT Referral card

0.282 (0.152 – 0.391)
0.059 (0.030 – 0.087)
0.052 (0.026 – 0.076)

0.282 (0.152 – 0.391)
0.167 (0.087 – 0.240)
0.136 (0.070 – 0.197)
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HIVST Choice
PITC
VCT
50+ years: Non-AIDS stage
50+ years: AIDS stage
HIV Test Sensitivity (%)
Initial Test
Confirmatory test
Tie-breaker test
Receive confirmatory test

0.227 (0.121 – 0.321)
0.151 (0.078 – 0.217)
0.063 (0.032 – 0.093)

0.312 (0.171 – 0.430)
0.250 (0.134 – 0.351)
0.033 (0.017 – 0.049)

0.019 (0.009 – 0.028)
0.028 (0.014 – 0.042)

0.010 (0.005 – 0.015)
0.015 (0.008 – 0.023)
85–87

OraQuick
KHB colloidal Gold
First Response 1-2.0
Uni-Gold

92.00 [66.00 – 99.00]
100.00 (97.40 – 100.00)
100.00 (97.40 – 100.00)
96.40 [91.8 – 98.8]

Community-based†
Facility-based‡

0.900 (0.750 – 1.00)
1.000 (0.500 – 1.000)

21,181,182

Non-AIDS
AIDS

0.641 (0.401 – 0.785)
0.785 (0.536 – 0.900)

22

Assumption

Linkage to care
102

ART initiation
Non-AIDS
AIDS

0.830 (0.588 – 0.930)
0.930 (0.735 – 0.981)

Non-AIDS
AIDS

0.004 (0.003 – 0.006)
0.006 (0.005 – 0.008)

Switch to second Line ART

Loss to follow up (LTFU)
Pre-ART
30-49 years

50+ years
On ART
30-49 years

159

14,183–185

Asymptomatic
Symptomatic
AIDS

0.029 (0.015 – 0.044)
0.040 (0.020 – 0.059)
0.043 (0.022 – 0.059)
0.025 (0.012 – 0.037)

0.025 (0.012 – 0.037)
0.033 (0.017 – 0.049)
0.036 (0.018 – 0.054)
0.022 (0.011 – 0.033)

Asymptomatic
Symptomatic

0.015 (0.007 – 0.022)
0.020 (0.010 – 0.030)

0.012 (0.006 – 0.018)
0.017 (0.008 – 0.025)
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AIDS
50+ years
Disability weights
Pre-ART and LTFU

0.022 (0.011 – 0.033)
0.012 (0.006 – 0.019)

0.018 (0.009 – 0.027)
0.012 (0.006 – 0.018)
105,106

Asymptomatic
Symptomatic
AIDS

On ART
Costs (US$ 2017)
HIV testing§
Initial test

0.004 (0.002 – 0.007)
0.023 (0.011 – 0.034)
0.049 (0.024 – 0.073)
0.004 (0.002 – 0.007)

32,95,186

18.73 (9.37 – 28.10)
20.87 (10.44 – 31.31)
14.74 (7.37 – 22.12)
13.11 (6.55 – 19.66)
6.77 (3.39 – 10.16)
6.77(3.39 – 10.16)
186
Confirmatory test
6.75 (3.37 – 10.12)
186
Tiebreaker
7.74 (3.87 – 11.62)
¶
110
Pre-ART
23.13 (10.80 – 43.33)
110
First-line ART
33.01 (19.24 – 59.03)
110
Second-Line ART
49.02 (23.06 – 82.59)
¥
187
Death
1,692.62 (483.61 – 2,901.63)
Abbreviations: DALYs = disability adjusted life-years; HIVST = HIV self-testing; VCT = voluntary counseling and testing; PITC =
provider-initiated testing and counseling; ART = Antiretroviral therapy
*Parameters reflect monthly probabilities, costs and disability weights unless specified otherwise
†PLWH are reached in the community for HIV testing
‡PLWH are visit the health facility for HIV testing
§Cost is applied per test uptake
¶Costs included are in Appendix
¥Funeral costs incurred by the family
Kit Delivery
Coupon Delivery
Referral card
HIVST Choice
PITC
VCT

90

Table 4: Undiscounted base case cost-effectiveness results¶
Domain*
HIV Testing Strategy
Costs ($) Incremental Cost ($) DALYs Lost

DALYs Averted ICER†

Female sex workers
Health facility

Combination

Community

No Testing
Voluntary testing
Provider-initiated testing
HIVST Choice
HIV testing referral card
HIVST coupon delivery
HIVST kit delivery

$
$
$
$
$
$
$

1,693
2,909
7,101
7,561
9,143
9,192
10,110

$ 8,418

45.36
43.07
35.09
34.09
31.18
31.10
29.31

16.05

w_dominated
w_dominated
w_dominated
w_dominated
w_dominated
$ 520

Long distance truck drivers
Health facility

No testing
$ 1,693
45.61
Voluntary testing
$ 2,580
43.86
w_dominated
Provider-initiated testing $ 3,520
41.99
w_dominated
Combination
HIVST Choice
$ 4,073
40.89
w_dominated
HIVST coupon delivery $ 5,021
38.99
w_dominated
HIV testing referral card $ 5,123
38.78
w_dominated
Community
HIVST kit delivery
$ 7,549
$ 5,856
33.81
11.80
$ 500
Abbreviations: HIVST = HIV self-testing, DALYs = Disability Adjusted Life Years, ICER = Incremental cost effectiveness ratio;
w_dominated = weakly dominated
*Strategies are classified by setting including health facility only, community only and a combination of both the health facility and
the community setting.
†ICER is expressed as incremental cost/DALYs averted.
‡Life expectancy at 30 years.
§Compared to “No testing” strategy.
¶Costs and health benefits are undiscounted
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Table 5: Discounted base case cost-effectiveness results¶
Domain*
HIV Testing Strategy
Costs ($) Incremental Cost ($) DALYs Lost

DALYs Averted ICER†

Female sex workers
Health facility

Combination

Community

No Testing
Voluntary testing
Provider-initiated testing
HIVST Choice
HIV testing referral card
HIVST coupon delivery
HIVST kit delivery

$
$
$
$
$
$
$

1,404
2,028
4,301
4,565
5,502
5,535
6,107

$ 2,896
$
264

$ 1,541

21.93
20.70
16.20
15.69
13.88
13.83
12.70

5.73
0.51

2.98

w_dominated
$ 500
$ 510
w_dominated
w_dominated
$ 520

Long distance truck drivers
Health facility

No testing
$ 1,425
22.11
Voluntary testing
$ 1,911
21.11
w_dominated
Provider-initiated testing
$ 2,447
19.99
w_dominated
Combination
HIVST Choice
$ 2,769
19.32
w_dominated
HIVST coupon delivery
$ 3,332
18.18
w_dominated
HIV testing referral card
$ 3,392
18.04
w_dominated
Community
HIVST kit delivery
$ 4,951
$ 3,526
14.77
7.34
$ 480
Abbreviations: HIVST = HIV self-testing, DALYs = Disability Adjusted Life Years, ICER = Incremental cost effectiveness ratio,
w_dominated = weakly dominated
*Strategies are classified by setting including health facility only, community only and a combination of both the health facility and
the community setting.
†ICER is expressed as incremental cost/DALYs averted.
‡Life expectancy at 30 years.
§Compared to “No testing” strategy.
¶Costs (2017 $) and health benefits are discounted at 3% per annual.
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Figure 3: Markov model structure

Abbreviations: LTFU = Loss to follow up; ART = Antiretroviral therapy
Figure 3 shows the model structure with clinical stages of HIV disease progression defined as follows: Asymptomatic Early
(corresponding with CD4 count >500 cells/μL); Asymptomatic Late (corresponding with CD4 count >350 - 500 cells/μL);
Symptomatic (CD4 count 200-350 cells/μL); and AIDS (CD4 count 200 cells/μL)). Engagement in HIV care was characterized as
undiagnosed, diagnosed, linked to care, on first line ART, on second-line ART, lost from care, and death (not shown). The cohort
starts at undiagnosed stages transitions through the health states using probabilities at a monthly cycle. HIV testing strategies impact
the probability of being diagnosed.
Represents the probability of a FSW or truck driver getting diagnosed and the probability varied across strategies
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Figure 4: Schematic for the HIV testing algorithm

Figure 4 illustrates the possible pathways for HIV testing algorithm used in this study. For example, an initial cohort of undiagnosed
truck drivers with CD4>500, a fraction of the cohort can be reached by an HIV testing strategy and among those that are reached, an
initial HIV test is offered and if the test is reactive, they perform a confirmatory test or a tiebreaker in a case of inconsistency between
the initial test and the confirmatory test. Since all the initial cohort included people living with HIV, fractions of the cohort that are not
reached, refused the test, or got a false negative remain undiagnosed.
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Figure 5: Model validation with data for the overall population of people living with HIV
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Figure 5 shows results for the model validation. I validated the model by corroborating the life expectancy at 30 years for truck drivers
and FSWs living with HIV to data on overall population of PLWH in Rwanda. The blue trend band shows the confidence intervals of
life-expectancy for people living with HIV in Rwanda who are diagnosed at 32 years of age. 113 Overall, based on clinical stage at the
time of HIV diagnosis, The life expectancy in the model was comparable to the data from Rwanda.
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Figure 6: One-way sensitivity analysis of Kit delivery compared to the HIVST Choice among female sex workers
Base case ICER = $ 517
Cost first-line ART [$19.24 - $59.03]
WTP = 1xGPD per capita, $570
Cost second-line ART [$23.06 - $82.59]
Cost of death [$483.61 - $2,901.63]
Disease progression to symptomatic [0.014 - 0.043]
Disease progresssion to AIDS [0.012 - 0.035]
Disability weight on ART [0.002 - 0.007]
LTFU at non-AIDS stage on ART [0.004 - 0.007]
Disability weight at AIDS stage not on ART [0.024 - 0.073]
Return to care ART [0 - 1]
Reached FSWs at AIDS stage [0.047 - 0.135]
WTP = 3xGPD per capita, $4,710
HIV test uptake, Kit Delivery, AIDS stage [0.152 - 0.391]
Switching to second line ART at AIDS stage [0.005 - 0.006]
HIV test uptake, HIVST Choice, AIDS stage [0.171 - 0.430]
HIV test uptake, Kit Delivery, non-AIDS stage [0.104 - 0.282]
Confirmatory test [0.5 - 1]
$Range

$1,000.00

$2,000.00

$3,000.00

$4,000.00

$5,000.00

Incremental Cost-effectiveness Ratio ($ 2017)

Abbreviations: ART = Antiretroviral Therapy, LTFU = Loss to follow-up, HIVST = HIV self-testing; ICER = Incremental Cost
Effectiveness Ratio, WTP = willingness to pay
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Figure 7: One-way sensitivity analysis of Kit delivery compared to the No testing strategy among truck drivers
Base case ICER = $ 481
Cost second-line ART [$23.06 - $82.59]
WTP = 1xGPD per capita, $570
Cost of death [$483.61 - $2,901.63]
Disease progression to symptomatic [0.014 - 0.043]
Disease progresssion to AIDS [0.012 - 0.035]
Disability weight for non-AIDS stage, on ART [0.002 - 0.007]
LTFU at non-AIDS stage on ART [0.006 - 0.01]
Disability weight at AIDS stage not on ART [0.024 - 0.073]

WTP = 3xGPD per capita, $4,710

Annual discounting [0.00 - 0.05]
Switching to second line ART at non-AIDS stage [0.003 - 0.005]
Disability weight at symptomatic stage [0.011 - 0.034]
Variable Description
$-

$1,000.00

$2,000.00

$3,000.00

$4,000.00

Incremental Cost-effectiveness Ratio (2017, $)
Range

Abbreviations: ART = Antiretroviral Therapy, LTFU = Loss to follow-up, HIVST = HIV self-testing; ICER = Incremental Cost
Effectiveness Ratio, WTP = willingness to pay
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Paper three
Table 6: LTFU strategies with associated risk reduction and costs
Strategy
Description
LTFU RRR
% (range)
No Intervention
Standard of care that offers only free
—
ART at the health facility

Cost, 2017 USD (range)
First-line ART
Second-line ART
17.38
32.88
(8.69 – 26.07)
(16.44 -49.32)

Source
14

ART Delivery

Home free ART delivery by
community health workers

40
(29 – 49)

16.62
(8.31 – 24.93)

32.12
(16.06 – 48.18)

133

ART Delivery +
Nutrition

Home free ART delivery by
community health workers plus
nutrition supplement

71
(53 – 88)

46.62
(23.31 – 69.93)

62.12
(31.06 – 93.18)

134

Tracing + Transport

Free ART, tracing patients that miss
appointments with transport
reimbursement.

22
(7–36)

24.71
(12.36 – 37.07)

40.21
(20.11 – 60.32)

135

46
(22 – 63)

26.14
(13.07 – 39.21)

41.64
(20.82 – 62.46)

136

Free ART, treatment for
41
23.51
39.01
opportunistic infections, transport
(12 – 75)
(11.76 – 35.27)
(19.51 – 58.52)
cost reimbursement, and breakfast.
Abbreviations: ART = Antiretroviral therapy; RRR = Relative Risk Reduction; LTFU = Loss to follow up

137

Tracing + Medical Care Free ART, tracing patients that miss
appointments with free medical care
for opportunistic infections
Medical Care +
Transport + Breakfast
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Table 7: Monthly parameter inputs
Parameter*

Baseline (range)

Initial distribution, %
Asymptomatic Early
Asymptomatic Late
Symptomatic
AIDS

LTFU
30-49 years: non-AIDS

30-49 years: AIDS

50+ years

Beta

94,158

Beta

83

Beta

159

0.013 (0.007 – 0.020)
0.029 (0.014 – 0.043)
0.023 (0.012 – 0.035)

Switch to second line ART
Non-AIDS
AIDS

Source

28.8 [41.8]
19.6 [25.3]
19.7 [21.1]
31.9 [11.6]

Disease progression
Asymptomatic Late
Symptomatic
AIDS

Distribution

0.004 (0.003 – 0.006)
0.006 (0.005 – 0.008)
Beta

No Intervention
ART delivery
ART delivery + Nutrition
Tracing + Transport
Tracing + Medical care
Medical care + Transport + Breakfast

0.011 (0.008 – 0.013)
0.006 (0.005 – 0.007)
0.003 (0.001 – 0.005)
0.008 (0.007 – 0.010)
0.006 (0.004 – 0.008)
0.006 (0.003 – 0.009)

14

No Intervention
ART delivery
ART delivery + Nutrition
Tracing + Transport
Tracing + Medical care
Medical care + Transport + Breakfast

0.021 (0.016 – 0.027)
0.013 (0.011 – 0.015)
0.006 (0.002 – 0.010)
0.016 (0.013 – 0.019)
0.011 (0.008 – 0.016)
0.012 (0.005 – 0.018)

14

No Intervention
ART delivery
ART delivery + Nutrition

0.004 (0.003 – 0.005)
0.002 (0.001 – 0.003)
0.001 (0.001 – 0.002)

14

133
134
135
136
137

133
134
135
136
137

133
134
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Tracing + Transport
Tracing + Medical care
Medical care + Transport + Breakfast

0.003 (0.002 – 0.003)
0.002 (0.001 – 0.003)
0.002 (0.001 – 0.003)

Costs (US $, 2017)
FWS on first-line ART

FWS on second-line ART

135
136
137

Gamma
No Intervention
ART delivery
ART delivery + Nutrition
Tracing + Transport
Tracing + Medical care
Medical care + Transport + Breakfast

17.38 (8.69 – 26.07)
16.62 (8.31 – 24.93)
46.62 (23.31 – 69.93)
24.71 (12.36 – 37.07)
26.14 (13.07 – 39.21)
23.51(11.76 – 35.27)

No Intervention
32.88 (16.44 -49.32)
ART delivery
32.12 (16.06 – 48.18)
ART delivery + Nutrition
62.12 (31.06 – 93.18)
Tracing + Transport
40.21(20.11 – 60.32)
Tracing + Medical care
41.64 (20.82 – 62.46)
Medical care + Transport + Breakfast
39.01 (19.51 – 58.52)
Abbreviations: ART = Antiretroviral drugs; LTFU = Loss to follow up; FSW = Female sex workers
*Parameters reflect monthly probabilities, costs and disability weights unless specified otherwise

110
110,133
110,133,161
110,160
110,160,188
110,137,160,188

110
110,133
110,133,161
110,160
110,160,188
110,137,160,188
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Table 8: Undiscounted base case results for strategies to reduce LTFU from ART programs among female sex workers
Strategy
Cost
Incremental cost DALYs Lost DALYs Averted ICER
No Intervention
$ 4,664.02
28.41
ART delivery
$ 5,533.25 $
869.23
26.36
2.05
$
400
Tracing + Transport
$ 6,842.64
27.44
s_dominated
Medical care + Transport + Breakfast $ 7,299.20
26.29
w_dominated
Tracing + Medical care
$ 8,218.37
25.92
w_dominated
ART delivery + Nutrition
$ 16,292.13 $ 10,758.88
23.40
2.96
$ 3,200
Abbreviations: LTFU = Lost to follow up; ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER =
Incremental cost-effectiveness ratio; w_dominated = weakly dominated; s_dominated = strongly dominated
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Table 9: Discounted base case results for strategies to reduce LTFU from ART programs among female sex workers
Strategy
Cost
Incremental cost
DALYs Lost DALYs Averted ICER
No Intervention
$ 2,994.56
11.52
ART delivery
$ 3,460.73 $
466.17
10.55
0.98
$ 470
Tracing + Transport
$ 4,386.60 -11.05
s_dominated
Medical care + Transport + Breakfast $ 4,606.21 -10.51
w_dominated
Tracing + Medical care
$ 5,173.28 -10.35
w_dominated
ART delivery + Nutrition
$ 10,022.73
$ 6,561.99
9.27
1.28
$ 5,100
Abbreviations: LTFU = Lost to follow up; ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER =
Incremental cost-effectiveness ratio; w_dominated = weakly dominated; s_dominated = strongly dominated
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Table 10: Multi-way sensitivity analysis of LTFU strategies with low bound parameter values considered
Strategy
Cost
Incremental cost DALYs Lost DALYs Averted ICER
No Intervention
$ 1,497.28
10.94
ART delivery
$ 1,632.37 $
135.00
10.30
0.64
$ 210.00
Tracing + Transport
$ 2,020.06 -10.70
s. dominated
Medical care + Transport + Breakfast $ 2,069.35 -10.80
s. dominated
Tracing + Medical care
$ 2,302.64 -10.47
s. dominated
ART delivery + Nutrition
$ 4,461.36 $ 2,829.00
9.54
0.76
$ 3,720.00
Abbreviations: LTFU = Lost to follow up; ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER =
Incremental cost-effectiveness ratio; w_dominated = weakly dominated; s_dominated = strongly dominated
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Table 11: Multi-way sensitivity analysis of LTFU strategies with upper bound parameter values considered
Strategy
Cost
Incremental cost DALYs Lost DALYs Averted ICER
No Intervention
$ 4,491.84
12.23
ART delivery
$ 5,479.14 $
987.29
10.94
1.28
$ 770
Tracing + Transport
$ 7,018.73 -11.37
s. dominated
Medical care + Transport + Breakfast $ 8,637.60 $ 3,217.41
10.37
1.19
$ 2,670
Tracing + Medical care
$ 8,696.55 -9.74
s. dominated
ART delivery + Nutrition
$ 17,298.98 $ 8,602.43
8.88
0.86
$ 9,950
Abbreviations: LTFU = Lost to follow up; ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER =
Incremental cost-effectiveness ratio; w_dominated = weakly dominated; s_dominated = strongly dominated
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Table 12: Undiscounted cost-effectiveness of LTFU strategies after adjusted for misclassification of patients
Strategy
Cost
Incremental cost
DALYs Lost DALYs Averted ICER
No Intervention
$ 6,500.45
24.97
ART delivery
$ 7,431.96 $
931.51
22.97
2.00
$
460
Tracing + Transport
$ 9,231.43
23.96
s_dominated
Medical care + Transport + Breakfast $ 9,625.14
22.91
w_dominated
Tracing + Medical care
$ 10,684.33
22.60
w_dominated
ART delivery + Nutrition
$ 19,338.22 $ 11,906.26
20.80
2.18
$ 5,400
Abbreviations: LTFU = Lost to follow up; ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER =
Incremental cost-effectiveness ratio; w_dominated = weakly dominated; s_dominated = strongly dominated
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Table 13: Discounted cost-effectiveness of LTFU strategies after adjusted for misclassification of patients
Strategy
Cost
Incremental cost DALYs Lost DALYs Averted ICER
No Intervention
$ 3,987.28
9.93
ART delivery
$ 4,414.55 $
427.27
9.09
0.84
$
500
Tracing + Transport
$ 5,638.55
9.50
s_dominated
Medical care + Transport + Breakfast $ 5,780.22
9.06
w_dominated
Tracing + Medical care
$ 6,407.93
8.94
w_dominated
ART delivery + Nutrition
$ 11,482.61
$ 7,068.06
8.21
0.88
$ 8,000
Abbreviations: ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER = Incremental cost-effectiveness ratio;
w_dominated = weakly dominated; s_dominated = strongly dominated
Tables 12 and 13 show cost-effectiveness results after adjusting for LTFU misclassification. I applied a probability weight of 0.43,
derived from 1 – proportion LTFU who die – proportion LTFU who self-transfer from site. In sub-Saharan Africa its estimated that
20.8% and 35.9% of patients recorded as LTFU have died or self-transferred to another ART clinic.19
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Figure 8: Model structure

Abbreviations: ART = Antiretroviral Therapy; LTFU = Loss to follow up
Represents the probability of LTFU, which varies across strategies
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Figure 9: One-way sensitivity analysis of ART delivery vs No intervention (standard of care)
Base case ICER = $ 476
WTP = 1xGPD per capita, $570

Second Line ART Drugs ($11.92 - $35.75)

LTFU Relative Risk Reduction (0.29 - 0.49)

Discount rate (0 - 0.05)

Probability of switching to second line ART (0.003 - 0.006)
WTP = 3xGPD per capita, $4,710

First Line ART Drugs ($4.17 - $12.5)
$-

$1,000.00

$2,000.00

$3,000.00

$4,000.00

$5,000.00

Incremental cost-effectiveness ratio, 2017 $
Range

Abbreviations: ART = Antiretroviral Therapy; LTFU = Loss to follow up; ICER = Incremental Cost-effectiveness Ratio, WTP =
willingness to pay
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Figure 10: Cost-effectiveness acceptability curves*

Abbreviations: ART = Antiretroviral Therapy
*Cost-effectiveness acceptability curves of other strategies were not included because their probabilities of cost-effectiveness were
always lower than the three strategies indicated in the figure. However, I included the plot in the supplementary material (Figure S6).
Figure 10 shows cost-effectiveness acceptability curve generated from the probabilistic sensitivity analysis. When the WTP was
<$500, No Intervention had the highest probability of cost-effectiveness; $500-$4,600 ART Delivery was more likely to be costeffective; and >$460 the ART Delivery + Nutrition Supplement had a higher probability of cost-effectiveness.
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Figure 11: Scatter plot for incremental costs and effectiveness (No Intervention vs ART Delivery)

Abbreviations: ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; WTP = Willingness to Pay
Figure 11 shows the cost-effectiveness plane with majority of the data points for the joint distribution of incremental costs and
incremental effectiveness fall in the Northeastern and Southeastern quadrants of the plane, indicating that the ART delivery strategy
averted DALYs and may also be cost-saving.
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Supplementary material
This document contains supplemental information including the justification for analytical decisions, analyses, and results.
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Supplementary materials for paper one
Table S1: Summary of justifications for analytical decisions
Analytical Decision
Study perspective
This study was conducted based on a societal perspective

Inflation adjustment

Recommendation
The WHO recommends conducting cost-effectiveness
studies from a societal perspective, which takes into
account direct health (e.g., clinical services) and non-health
(e.g., patient time) related costs of a health intervention for
a society as a whole regardless of who is paying.1
The WHO recommends the Gross Domestic Product
deflator to be used for inflation adjustment of health
sector costs because it takes into account changes in prices
in the whole economy.1

The GDP deflator was used for inflation adjustment because it is the
only available and recommended index inflation adjustment in lowincome settings such as Kenya. The Gross Domestic Product (GDP)
deflator is a price index which measures the annual change in prices for
a quantity goods and services produced in the economy including those
exported to other countries. The index is more comprehensive as it
takes into account government and household consumption and
international trade.
Currencies used for measuring and reporting costs
The WHO recommends that costs are valued in
international dollars to enable comparison of results
We reported costs in international dollars to facilitate comparison of
across countries/settings. For interventions that are
specifically local, and all prices are collected in local
cost-effectiveness results across other countries in the region. An
currency, WHO recommends using the local currency
international dollar is a hypothetical currency, which has the same
since it is more practical and useful to local policy
value as the US dollar and has the same purchasing power in every
makers.1
country. The international dollar is used in cost-effectiveness analysis
because it enables cross-country comparisons of costs easier and
interventions easier. The purchasing power of 1 I$ is the same in all
countries. Costs reported in local currency are converted to
international dollars using the purchasing power parity (PPP) exchange
rate, which takes into account the country’s standards of living.
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Statistical model for estimating effectiveness

There is no gold standard statistical model that is
recommended for estimating relative risks for cohort
studies. However, the log-binomial model is
The Poisson regression model with a robust variance was used to
estimate the effectiveness of CHIVST. The Poisson regression model is recommended in literature since it generates more reliable
confidence intervals. But, given the challenges of
part of the generalized linear models and uses the log-link function.
convergence of the log-binominal model, the Poisson
Poisson regression model with a robust variance has been shown in
literature to generate similar results as the log-binomial model.2 We use model with robust-variance is recommended as an
alternative model.
a robust variance because the Poisson regression model does not
impose any restrictions to the estimated parameter and hence is likely
to overestimates the bounds of the estimate.3
Statistical model for estimating incremental costs
In literature, there is no consensus on a single model to
use for estimating mean costs per trial arm. However, the
generalized linear gamma model is commonly
The generalized linear gamma model was used to estimate the
recommended because it produces unbiased mean costs.
incremental costs. A review on regression models for analyzing cost
4
data found that the gamma GLM is preferred estimating costs. The
gamma model does not assume equal variance across datasets and is
not affected by skewed distribution of the data.

113

Table S2: Methods and recommendations for inflation adjustment
Method

Description

Advantages

Disadvantages

The
consumer
price index
(CPI)

The CPI is a statistical
estimate that reflects the
change in prices of a fixed
basket of consumer goods
and services. The goods
and services considered for
the index are representative
of the usual consumer
expenditures. The CPI is
calculated on a monthly
basis and weights are used
to generate the aggregated
annual CPI.

1 – Most
frequently used
method to
account for
general inflation
and easy to
understand.

1 – CPI depends only on a
fixed basket of consumer
goods and services selected,
which may not reflect all
the health care related costs.
For example, CPI takes into
account only out-of-pocket
but not all medical
expenditures.

The CPI uses the Laspeyres
price index—an arithmetic
mean for a fixed basket of
goods and services and
adjusted periodically to
take into account changes
in consumption and
production of goods and
services.
The CPI has a medical
component, which takes
into account differences in
prices for medical sector.

2 – CPI can be
generated for
specific
commodities. For
example, the
Medical CPI can
be computed for
only medical
costs (drugs,
physician, and
nurse salaries)

2 – CPI may not be
appropriate if the rate in
change of price for a
specific resource is not the
same as the general price
inflation.
3 – The index does not take
into account the substitution
effect where consumers are
more likely to substitute
goods and services that are
pricy for cheaper goods,
hence overestimating the
inflation.
4 – The CPI medical
component has been
reported to have
measurement errors but also

Recommendations and
Decision
WHO:
Recommends the Gross
Domestic Product
deflator to be used for
inflation adjustment of
health sector costs
because it takes into
account changes in prices
in the whole economy.

Source
1,5

US Panel:
Recommends inflation
adjustment to be done
using the Personal Health
Care expenditure deflator
because it accurately
reflects the changes in
prices in the medical
sectors as compared to
the Consumer Price Index
or Personal Consumption
Expenditure. In case the
Personal Health Care is
not available for the
current year, the panel
recommends using the
Personal Health Care up
to the most recent year
and then use the Personal
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The Gross
Domestic
Product
(GDP)
deflator

The GDP deflator is a price
index which measures the
annual change in prices for
a quantity goods and
services produced in the
economy including those
exported to other countries.
The index is more
comprehensive as it takes
into account government
and household
consumption and
international trade.

The GDP uses the Fisher’s
index—geometric mean of
prices of goods and
services in the base year
and current year. Since the
index takes into account
prices in the base and
current, it reduces the
substitution bias—clients
substitute cheaper goods
for expensive goods.
Personal
The PCE price index
Consumption (Fisher’s index) is used to
Expenditure reflect all personal
(PCE) price
expenditures including
index
medical, education and
other services as compared

1 – GPD deflator
takes into the
substitution
effect.
2 – GDP deflator
measures the
annual price
change and
incorporates the
whole aspect of
the economy.

1 - The PCE
includes more
expenditures
including those
paid by the third
party (not

it is not available in many
countries including Kenya.
1 – The GDP deflator
regarded as the best option
among all methods, but it
also does not take into
account the quality of the
goods and services and may
be cumbersome to calculate
all the prices and quantities
in the economy.

1 - The PCE index does not
include government
investments and
expenditures.

Consumption
Expenditure.5
1,5

World Bank:
No recommendations
Decision:
The GDP deflator is used
because it is the only
available and
recommended index
inflation adjustment in
low-income settings such
as Kenya.

5,6
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to the CPI that only
accounts for consumption
items.

Personal
Health Care
(PHC)
expenditure
deflator

The rate of
wage
inflation

The rate of
inflation for

government),
which makes it a
better estimate
than the CPI.

2 - More
appropriate when
adjusting for
changes in the
purchasing
power for
personal
consumption.
The PHC index is a more
1 – The PHC
specific and includes
index is more
personal health
specific and
expenditures (out-of-pocket appropriate for
and third-party payments). medical related
This index is built on the
expenditures
CPI-medical component,
compared to the
but the PHC also includes
general PCE or
the third-party
CPI.
expenditures.
This approach only
1 – The rate of
measures the average
wage inflation is
increase in the wages in the more specific
whole economy or a given
and may be more
sector in the economy.
accurate and
appropriate for
wage adjustment.
This approach in applicable 1 – The method
to a specific industry or
is more specific
sector. Some countries

1 – The PHC is not
available in many countries
and in the United States, the
index is estimated after a 2year lag.

5,6

1 – The rate of wage
inflation is too narrow to
apply as the general
inflation index.

1

2 – The index does not
cover all potential costs to

1
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specific
products

produce the index for the
health sector (goods and
services).

and may be more
accurate.

be applied broadly as the
general inflation index.

3 - The index is also not
readily available in most of
the countries especially
developing countries such
as Kenya.
WHO = World Health Organization guide to Cost-effectiveness analysis
US Panel – The US Panel on Cost-effectiveness in Health and Medicine
World Bank – Cost-effectiveness recommendation for disease control priorities
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Table S3: Currencies used for measuring and reporting costs.
Method

Description

Advantages

Disadvantages

International An international dollar is a
dollar (I$)
hypothetical currency,
which has the same value
as the US dollar and has
the same purchasing power
in every country. The
international dollar is used
in cost-effectiveness
analysis because it enables
easier cross-country
comparisons of costs and
interventions. The
purchasing power of 1 I$ is
the same in all countries.
Costs reported in local
currency are converted to
international dollars using
the purchasing power
parity (PPP) exchange rate,
which takes into account
the country’s standards of
living.

1 - The
international dollar
enables crosscountry comparison
of costs and
interventions
especially when
costs are collected
from multiple
sources and
reported in
different
currencies.

1 - A large body of costeffectiveness studies use
market exchange rates and
report costs in US dollars,
which makes comparison
with studies that use
international dollars a
challenge.

US dollar
(US $)

1 – The US dollar
is more relatable
given that prices of
most of
commodities on the
international

The US dollar is used in
many cost-effectiveness
studies given because most
goods and services on
international markets are
traded in US dollars.

3 – Some regions don’t
have PPP exchange rates,
which may limit the use of
international dollars
2 – The international dollar
is a hypothetical currency
and costs in real life are
measured in US dollars.

1 – The US dollar does not
account for differences in
costs of goods that are not
traded on international
markets such as labor.
Salaries vary across
countries, and it is not

Recommendations and
Decision
WHO:
Recommends that costs
are valued in
international dollars to
enable comparison of
results across
countries/settings. For
interventions that are
specifically local, and all
prices are collected in
local currency, WHO
recommends using the
local currency since it is
more practical and
useful to local policy
makers.

Source
1,7

US Panel:
No recommendations
World Bank:
Recommends using the
international dollar and
they base their
recommendation on the
WHO recommendation.

1,7

Decision:
I decided to report costs
in international dollars to
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Local
currency
(Kenyan
Shilling)

Cost-effectiveness studies
have used local currencies
especially when the
intervention is locally
funded, and prices are all
valued in local currency.

market are traded in possible to assign a US
US dollars.
dollar value that would
represent the cost of labor
2 – The US dollar
in all countries.
is appropriate to if
all costs are coming
from one country
and there’s no need
for comparison of
costs also multiple
countries.
1 – Use of local
1 – Local currency is only
currency is useful
practical to use when all
and practical to
costs are collected and
local policy makers reported in local currencies.
given that budgets
are done in local
2 – The cost-effectiveness
currency.
results are less likely to be
generalizable and compared
to other similar
interventions in other
setting when costs are
reported in local currency.

facilitate comparison of
cost-effectiveness results
across other countries in
the region. Truck drivers
are a mobile population
in the region and hence
this intervention could
be applied to another
country in East and
Southern Africa.
1

WHO = World Health Organization guidelines to Cost-effectiveness analysis
US Panel – The US Panel on Cost-effectiveness in Health and Medicine
World Bank – Cost-effectiveness recommendation for disease control priorities
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Table S4: Statistical models used in the literature to estimate the relative risk of binary outcomes in non-clustered
randomized controlled trials
Method

Description

logistic
The ordinary logistic regression
regression model is the most commonly used
model
model to estimate a binary
outcome, but it produces only
odds ratios instead of risk ratios
(relative risk). Odds ratios are
generated using a logit link
function—logarithm of the ratio
between success and failure of an
intended outcome. The link
function connects the model’s
outcome to its predictors.
A method was developed by Jun
Zhang to convert odds ratios
generated by the logistic
regression model to risk ratios
(relative risk),8 which has been
widely used in medical and public
health studies.
logThe log-binomial regression
binomial model is part of the Generalized
regression Linear Models that assumes a
model
linear relationship between the
outcome and the predictors using
the log link function. Since the
outcome in this study is binary,
the relationship between the
outcome and the predictors is non-

Advantages

Disadvantages

1 – The logistic
regression model is
easy, widely
acceptable, and able
to estimate relative
risks in situations
where more
advanced models
are not required.

1 – The method for
converting odds ratios
generated by the logistic
regression model is
likely to generate wide
confidence intervals and
has been found to be
inconsistent.9
2 – The converted
relative risk
overestimates the risk
ratio when the incidence
of the outcome is more
common (>10 percent)10

1 - The log-binomial
regression estimates
the relative risks,
which we need for
estimating the
incremental
effectiveness of the
intervention.

1 – The drawback of the
log-binomial model is
that in some situations it
does not converge to
produce the estimates.3
The issue of
convergence occurs
because the log-binomial
model imposes

Recommendations
Source
and Decision
8–10
There is no gold
standard statistical
model that is
recommended for
estimating relative
risks for cohort
studies. However, the
log-binomial model is
recommended in
literature since it
generates more reliable
confidence intervals.
But, given the
challenges of
convergence of the
log-binominal model,
the Poisson model with
robust-variance is
recommended as an
alternative model.
The Poisson model
overcomes the
problem of failure to
converge because it
does not impose any
restriction on the
estimated parameters.
We use a robust
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linear. To generate the linear
relationship, the link function
transforms the outcome by taking
the log of the mean of the
outcome.

2 - log-binomial
produces unbiased
estimates and
smaller confidence
intervals.

Since the outcome has been
transformed to a log of the mean
of the outcome, we exponentiate
the coefficients of the predictors
to estimate the relative risk of the
outcome for a unit change in the
predictor.

3 – Log-binomial is
also the most
commonly used
model in literature,
which makes our
study comparable
with other studies.

Poisson
Similar to the log-binomial model, 1 – The Poisson
regression the Poisson regression model is
regression model
model
part of the generalized linear
generates

restrictions on the
parameter space to
prevent probabilities
from exceeding 1 and
when the maximum
likelihood estimate
(MLE) occurs at the
boundary of the
parameter space, the
model fails to converge
to find/generate the MLE
estimate. Some studies
have developed
alternative methods to
overcome the issue of
convergence. For
example, modifying the
data so that the MLE
estimate is within the
parameter space (COPY
method).12,13 The COPY
method uses multiple
simulations to replicate
the original data and
estimate the relative
risks. However,
alternative models have
been recommended than
using the COPY method.
1 – Poisson regression
model is more preferred
when the prevalence of

variance to minimize
the likelihood of
overestimating
parameters. The
Poisson regression
model in equation (1)
was used to estimate
the relative risk. The
model uses a log link
function, which links
the binary dependent
outcome with the
linear predictors. In
this case, the log link
function exponentiates
the linear predictors to
generate relative risk
estimates per linear
predictor.11

2,14
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with a
robust
variance

models and uses the log-link
function. Poisson regression
model with a robust variance has
been shown in literature to
generate comparable results as the
log-binomial model.2 The robust
variance is used because the
Poisson regression model does not
impose any restrictions to the
estimated parameter and hence is
likely to overestimate the bounds
of the parameter estimate.3

comparable relative
risk estimates to the
log-binomial model
and is recommended
in literature as the
ideal substitute
when the logbinomial fails to
converge.

the outcome is low but in
our study the preference
is high. However, the
model is still able to
generate correct
estimates in high
prevalence outcomes.
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Table S5: Statistical models used in the literature to estimate mean costs in randomized controlled trials
Method

Description

Advantages

Arithmetic
mean

This method includes the
summing up of total costs per
trial arm and calculating the
mean per trial arm. The
means are compared to
determine the difference
between the two arms.

1 – This
method is
simple and
easy to
implement

The ordinary
least squares
(OLS)
regression

The OLS regression model is
one of the commonly used
multivariate models for
estimating mean costs
between the 2 trials arms. The
OLS model is simple to
implement and takes in to
account the individual
characteristics of the
participants.

1 – The OLS
model
estimates
mean costs
difference
between trial
arms and
accounts for
variations
across
participants.

OLS model assumes equal
variance of costs across trial
arms and the predicted mean
is a linear combination of
coefficients and control
variables.

Disadvantages

Recommendations Source
and Decision
15
1 – The arithmetic method does In literature, there
not take into account the
is no consensus on
distribution of the costs and the a single model to
average my not be presentative use for estimating
of the true average cost per
mean costs per trial
participant. This is particularly arm. However, the
true if there are differences in
generalized linear
baseline characteristics between gamma model is
subjects in the trial arms.15
commonly
16
recommended
1 – OLS has a limitation of
because it produces
failure to take into account the
skewed distribution of costs and unbiased mean
costs.
since OLS is sensitive to
outliers (extreme costs), the
estimates may be innacurate.16
2 – OLS assumes equal
variance across arms, which
may not be always true.
This limitation of extreme costs
can be overcome by taking the
log of costs but in some
situations log of costs can does
not wotk.17 Such situations
include: 1) when observations
include zero costs; 2) when the
distribution of log of costs is
not normal; and 3) when there
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Generalized
linear
(gamma)
models
(GLM)

The generalized linear models
are used to overcome the
limitations of OLS models
(does not assume constant
variance and linear
combination of coefficients
and control variables).
GLM (gamma) model uses a
log link function which
characterizes the relationship
between the linear
combination of coefficients
and control variables with the
predicted outcome. Unlike the
OLS that models the log of
the mean cost, the gamma
models the mean of log cost,
which overcomes the
limitations OLS. To generate
the arithmetic, we exponential
the log of mean cost.

1 – The
gamma model
does not
assume equal
variance and
is not affected
by skewed
distribution of
the data.

are differences in the variance
of log of costs across trial arms.
1 – The GML models have a
limitation of failure to identify
the correct link function to use
prior to estimating the model.
However, the log-link function
has been shown to be the most
applicable. Further, a number of
diagnostic tests can be
conducted to identify the
correct link function These
include: Pregibon link test,19
which evaluates the linearity
response of the estimation and
the Hosmer-Lewshow test,
which estimates the bias in the
estimates.20

4,18–20

GLM distributions includes
Normal, Bernoulli, Binomial,
Poisson, Gamma and Inverse
Normal.18 A review on
regression models for
analyzing cost data found that
the gamma GLM is preferred
estimating costs.4
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Descriptive statistics: Table S6 shows descriptive statistics for key variables by trial arm (CHIVST and SOC). We performed the chisquare test for categorical variables, Mann-Whitney U test for differences in Medians, and Fisher’s exact test for small samples to test
for differences between CHIVST and SOC arm. The descriptive statistics show that participants are not statistically different across trial
arms.

Table S6: Descriptive statistics for the sample overall and by randomization arm
Variable

Total, n (column
%)
305

Clinic 1
Clinic 2

144 (47.2%)
161 (52.8%)

Total
Clinic where recruited

Age in years
Mean (SD)
Median (Range)
High school graduate
No
Yes
Mean trucking income per month (Kenyan Shillings)
8,000–15,999 KES
16,000–23,999 KES
24,000–55,000 KES
Number of years worked as truck driver
Mean (SD)
Median (range)
Clinic is on usual trucking route
No
Yes
Number of nights away from home in the past 30 days
Mean (SD)

37.0 (7.9)
36.0 (21.0 – 62.0)
196 (64.3%)
109 (35.7%)
15 (5.2%)
65 (22.6%)
208 (72.2%)
8.7 (7.1)
6.7 (1.0 – 38.9)
51 (16.8%)
253 (83.2%)
21.6 (5.6)

SOC Arm, n
CHIVST Arm, n P-value, chi(row %)
(row %)
square test
155 (50.8%)
150 (49.2%)
0.787
72 (46.5%)
72 (48.0%)
83 (53.5%)
78 (52.0%)
0.9891
36.9 (8.0)
37. 2 (7.8)
35.0 (21.0 – 60.0) 37.0 (24.0 – 62.0)
0.417
103 (66.5%)
93 (62.0%)
52 (33.5%)
57 (38.0%)
0.074*
12 (8.1%)
3 (2.1%)
33 (22.3%)
32 (22.9%)
103 (69.6%)
105 (75.0%)
0.6501
9.0 (7.8)
8.4 (6.3)
6.7 (1.0 – 38.9)
6.7 (1.0 – 37.0)
0.573
24 (15.6%)
27 (18.0%)
130 (84.4%)
123 (82.0%)
0.4951
21.3 (5.9)
21.8 (5.3)
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Median (range)
Came to the clinic specifically for HIV testing
No
Yes
Sexually active in the past 6 months
No
Yes
Married (legal or common law)
No
Yes
Has other regular partner(s) on the trucking route
No
Yes
Paid for sex in the past 6 months
No
Yes
Always used condoms when had sex in the past 6
months (among those that had sex)
No
Yes
Ever tested for HIV before
No
yes
Number of years since last HIV test among those tested
Mean (SD)
Median (range)
Ever self-tested for HIV among those who ever tested
No
Yes
*** p<0.01, ** p<0.05, * p<0.1
1Mann-Whitney U test
2
Fisher’s exact test

22.5 (0.0 – 30.0)

22.0 (0.0 – 30.0)

23 (2.0 – 30.0)
0.365

173 (56.7%)
132 (43.3%)

84 (54.2%)
71 (45.8%)

89 (59.3%)
61 (40.7%)
0.1162

6 (2.0%)
295 (98.0%)

1 (0.7%)
152 (99.3%)

5 (3.4%)
143 (96.6%)
0.998

51 (16.9%)
251 (83.1%)

26 (16.9%)
128 (83.1%)

25 (16.9%)
123 (83.1%)
0.619

163 (53.4%)
142 (46.6%)

85 (54.8%)
70 (45.2%)

78 (52.0%)
72 (48.0%)
0.789

126 (44.1%)
160 (55.9%)

65 (43.3%)
85 (56.7%)

61 (44.9%)
75 (55.1%)
0.358

250 (85.9%)
41 (14.1%)

127 (84.1%)
24 (15.9%)

123 (87.9%)
17 (12.1%)

25 (8.2%)
280 (91.8%)

10 (6.5%)
145 (93.5%)

15 (10.0%)
135 (90.0%)

0.259

0.9341
1.1 (1.6)
0.5 (0.1 – 12.0)

1.0 (1.4)
0.5 (0.1 – 7.4)

1.1 (1.9)
0.5 (0.1 – 12.0)
0.1712

276 (99.3%)
2 (0.7%)

142 (98.6%)
2 (1.4%)

134 (100.0%)
0 (0.0%)
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Missing data
Table S7 shows the total number of participants in the sample and the missing data in each variable in the total sample and per trial arm.
The percentage of patients missing data in all the variables is less than 10%. There is no consensus in literature on the minimum
percentage of missing data that could bias the results. Missing data can be accounted for in 2 ways: 1) deleting observations with missing
data or 2) imputing the missing data. Deleting observations with missing data may bias the results if the data is not missing completely
at random, which means that patients that have missing data could be different from those that have data, and this may bias the results.
Missing data may be imputed if it is not missing completely at random.

Table S7: Missing data in the total sample and across trial arms
Variable
Choice arm
Clinic visited
Age
Education level
Income
Years worked as a truck driver
Clinic is on usual track route
Number of nights away from home in the last 30 days
Visited clinic to test for HIV
Had sex in the last six months
Married
Has partner(s) on the trucking route
Paid for sex in the past 6 months*
Always used condoms when had sex in the past 6 months*
Ever tested for HIV before
Number of years since last HIV test among those tested
Ever self-tested

Total Sample
305
305
305
305
288
302
304
297
305
301
302
305
286
291
305
276
278

Total Missing, n (%)

Choice Arm

SOC Arm

17 (5.57%)
3 (0.98%)
1 (0.32%)
8 (2.6%)

10

4

7
3
1
4

4 (1.31%)
3 (0.98%)

2
2

2
1

9 (3.05%)
4 (1.36%)

7
3

2
1

29 (9.51%)
27 (8.85%)

18
16

11
11

* The question was asked among those that reported to have had sex in the last 6 months.
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Examining missing data in the analytical sample
Before accounting for the missing data, we first identified variables to include in our study. Explanatory variables (Table S8) were
considered based on theoretical and contextual significance to HIV testing uptake and this study. Among the four explanatory variables,
only one variable (payment for sex in the last six months) had missing data—9 (3%) participants were missing data of which 7 were in
the CHIVST arm and 2 in the SOC arm. We examined the missing data and found the data were missing completely at random across
trial arms. Considering that data was missing completely at random, we did not impute the missing data and patients with missing data
were excluded from the analysis.

Table S8: Justification for the variables included in the regression model
Variable
Clinic visited

Visited the clinic
to test for HIV
Paid for sex in
last 6 month
Age

Justification for inclusion
We included the clinic where participants tested because randomization was done at the clinic. There is a
possibility of differences across clinics that are not accounted for in the data that could impact the outcome. For
example, the staff at the clinic may treat patients differently.
We controlled for the reason a participant visited the clinic to account for those that may have tested for HIV
regardless of the intervention.
Payment for sex is a high-risk behavior that is associated with increased risk of acquiring HIV. In literature, men
who perceived to have a high risk of acquiring HIV were more likely to test for HIV compared to those that
perceived lower risk.21
Age is associated with HIV testing uptake with more older individuals likely to test for HIV compared to the
young, but the evidence is mixed. In some studies, adults compared to adolescents have shown more uptake of
HIV testing services,22 while others have shown more uptake among adolescents21,23 and age having no effect on
HIV testing.24 The variation in association of age with HIV testing uptake across studies could be attributed to
different age groups compared and study settings.

Univariate analysis
We conducted a univariate analysis to determine the individual effect of the variables on the uptake of HIV testing services. Table S9
shows that only four variables are statistically significant. Four variables (trial arm, clinic visited, if a patient visited the clinic to test for
HIV and payment for sex in the last 6 months) were statistically significant.
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Table S9: Univariate analysis on the HIV testing uptake
Variable
Choice arm
Clinic visited
Age
Visited clinic to test for HIV
Paid for sex in the past 6 months

Sample Size
305
305
305
305
286

Odds Ratio
2.56***
0.10***
1.00
8.01***
2.51***

95% CI
[1.40 – 4.66]
[0.04 – 0.23]
[0.97 – 1.04]
[3.54 – 18.5]
[1.38 – 4.54]

*** p<0.01, ** p<0.05

129

Economic costs data sources
Economic cost data (Table S10) came from peer-reviewed and grey literature. Costs incurred in the trial were first identified by reviewing
the report that summarized the implementation and findings from the trial. 25 Costs including SOC HIV test kit, HIV self-testing kit,
nurse salary, training, cell phone service, equipment (mobile phone) and patient time came from the trial report. 25 Costs for health
facility, health facility staff and overhead came from a costing analysis study within the same setting and study population. 26 Since SOC
HIV test kits were offered for free at the clinic, we identified the cost of SOC HIV test in Kenya 27 to examine the impact of SOC HIV
test kit cost variation in the sensitivity analysis. Finally, the cost of medical supplies (Table S11) came from an HIV testing study in
Kenya.28

Table S10: Selected data sources for HIV testing costs, derived from literature
Cost component
SOC HIV test kit

Country
Year of the data
Kenya
2015
Kenya
2012
HIV self-testing kit
Kenya
2015
Medical supplies
Kenya
2014
Kenya
2014
Nurse salary
Kenya
2015
One-time training
Kenya
2015
Health facility staff
Kenya
2016
Health facility
Kenya
2016
Overhead
Kenya
2016
Kenya
2016
Cell phone service
Kenya
2015
Equipment (mobile phone) Kenya
2015
Patient time
Kenya
2015
* Applicable only in the one-way sensitivity analysis

Currency
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
KES

Reported Unit
Per test kit
Per test kit
Per test kit
Per HIV test
Per HIV test
Per hour
Per patient
Per HIV test
Per HIV test
Per HIV test
Per patient
Per HIV test
Per patient
Per hour

Baseline [Range]
0.00
0.79*
7.54
0.14 [0.07 – 0.21] †
0.23 [0.12 – 0.35]
1.50
0.04
0.51
0.83
2.05
1.08‡
6.60
1.20

Source
25
27
25
28
28
25
25
26
26
26
26
25
25

165.72 [160.99 – 170.46] Trial data

†Applicable to patients that tested using self-administered oral HIV testing at the clinic.
‡ Applicable to patients that tested using self-administered oral HIV testing at home.
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Table S11: Cost of medical supplies
Type of cost performed
SOC

CHIVST (HIV self-test at the
clinic)

Medical supplies
Dual safe powdered gloves
Capillary tubes
Medimax cotton wool
Hand sanitizer
Alcohol swabs
Biohazard bags
lancets
Sum
Dual safe powdered gloves
Hand sanitizer
Biohazard bags
Sum

Unit
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested
per person tested

Cost (USD 2014)
$
0.06
$
0.04
$
0.01
$
0.06
$
0.03
$
0.02
$
0.01
$
0.23
$
0.06
$
0.06
$
0.02
$
0.14

Steps for converting costs from original currency to 2017 international dollars
1.
2.
3.
4.

Covert all costs to a common unit; per-patient cost
Covert cost estimate to Kenya currency using the exchange rate indicated in the data source
Adjust the costs for inflation to 2017 Kenyan currency year
Covert costs to 2017 international dollar currency year
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Table S12: Economic costs (2017 I$) considered in this study
Cost component†

Unit

SOC arm [Range]

SOC HIV test kit

Per patient
Per patient
Per patient
Per patient
Per patient
Per patient
Per patient
Per patient
Per patient
Per patient
Per patient
Per patient

0.00 [0.00 – 0.00]
1.43
—
0.42 [0.21 – 0.63]
2.27 [1.13 – 3.40]
—
1.10 [0.55 – 1.65]
1.72 [0.86 – 2.57]
—
—
4.24 [2.12 – 6.36]
2.51 [2.43 – 2.58]

HIV self-testing kit
Medical supplies
Nurse
One-time training
Health facility staff
Health facility
Equipment (Phone)
Cell phone service
Overhead
Patient time*

CHIVST arm [Range]
Source
SOC
Self-test (clinic)
Self-test (home)
25
0.00 [0.00 – 0.00]
—
—
27
1.43
—
—
—
15.52 [7.76– 23.28] 15.52 [7.76–23.28] 25
28
0.42 [0.21 – 0.63]
0.26 [0.13 – 0.38]
—
2.27 [1.13 – 3.40]
2.84 [1.42 – 3.40]
2.84 [1.42 – 3.40] 25
0.09 [0.05 – 0.14]
0.09 [0.05 – 0.14]
0.09 [0.05 – 0.14] 25
1.10 [0.55 – 1.65]
1.10 [0.55 – 1.65]
0.47 [0.24 – 0.71] 26
1.72 [0.86 – 2.57]
1.72 [0.86 – 2.57]
0.74 [0.37 – 1.12] 26
2.47 [1.23 – 3.70]
2.47 [1.23 – 3.70]
2.47 [1.23 – 3.70] 25
13.65 [6.82 – 20.47] 13.65 [6.82-20.47] 13.65 [6.82-20.47] 25
4.24 [2.12 – 6.36]
4.24 [2.12 – 6.36]
2.26 [1.13 – 3.38] 26
2.51 [2.43 – 2.58]
3.13 [3.04 – 3.22]
3.13 [3.04 – 3.22] 25

*Patient time cost was estimated based on average income (trial data) lost for the time spent at the time during the HIV testing process
which took 40, 50, and 50 minutes for participants that used the provider-administered test, self-testing at the clinic and self-testing at
home, respectively. Using data from the trial, we estimated the mean wages per hour, assuming a 40-hour week schedule and multiplied
it with the time spent at the clinic to calculate the patient time cost. The time spent at the clinic for HIV testing was significantly different
across trial arms. The cost of pre- and post-test counseling was estimated at 20 minutes and the actual HIV testing process was also
estimated at 20 minutes, for participants in both the CHIVST and SOC arm, totaling to 40 minutes per patient. 25 Participants that opted
for HIV self-testing had an additional time of 6.5 minutes to watch the demonstration video on how to use the HIV self-testing kit. After
watching the demonstration video, participants had questions regarding the HIV self-testing, and the total time was estimated at 10
minutes, including watching the video.25 We assumed that participants who tested from home used the same time (20 minutes) for the
actual HIV testing as those that tested from the clinic using the HIV self-testing. In summary, the HIV testing process took 40, 50, and
50 minutes for participants in the standard of care, HIV self-testing at the clinic and at home, respectively. We tested for the difference
in mean time across trial arms using the “t-test” and the difference was statistically significant.
†All cost boundaries, apart from patient time where we had access to personal level data from the trial, were estimated as 0.5 and 1.5 of
baseline value for the lower and upper bound, respectively because data sources did not report ranges or confidence intervals.
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Table S13: Results from the multi-way sensitivity analysis
Domain
Incremental Effectiveness (NNT)
Incremental Cost

Scenario*
N/A

Estimate
6.25

95% CI
[5.00 – 8.33]

Base case
Best case
Worst case

26.20
13.47
38.94

[23.32 – 29.09]
[11.89 – 15.05]
[34.74 – 43.13]

Base case
Best case
Worst case

163.77
84.19
243.36

[151.57 – 175.37]
[77.95 – 90.12]
[225.15 – 260.57]

Incremental cost-effectiveness ratio

Abbreviations: NNT = Number Needed to Treat; N/A = Not Applicable
*The base case considers costs at baseline value; best case considers only low bound costs; and worst case considers only the upper
bound costs for each cost component.
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Supplementary materials for paper two
Analytical decisions
Methodological approach: We used a mathematical model (a single cohort state transition model) due to its ability to examine
alternative strategies and project future costs and health benefits using multiple data sources. This methodology has been implemented
in literature to examine HIV prevention and treatment strategies,29,30 especially when observational data from one source is unavailable
to perform statistical analysis. Although the single cohort state transition model does not capture individual heterogeneity that reflects
the real world, it provides an insight in the potential cost-effectiveness of the strategies when data is unavailable to apply more advanced
methods such as micro-simulation.31
Model structure: The model has 24 health states (including death) based on natural history disease progression stratified based on CD4
cell count disease stages and engagement in clinical HIV care. The clinical stages of HIV natural disease progression are defined based
four CD4 cell count strata: Asymptomatic Early (corresponding with CD4 count >500 cells/μL); Asymptomatic Late (>350 - 500
cells/μL); Symptomatic (>200 – 350 cells/μL); and AIDS (<200 cells/μL)). The 4 CD4 strata enables estimation of health benefits and
economic costs for early diagnosis and engagement in care vs engagement in care at later stage of the disease.30,32 Patients diagnosed in
early stages of the disease and immediately initiated on ART experience lower risk of morbidity and mortality compared to those that
are diagnosed at late stages of the disease.33,34 However, CD4 stratification assumes similar behavior for the whole fraction of the cohort
within the stratum, which may not be the case. We include six stages of engagement in HIV care (undiagnosed, diagnosed, liked to care,
First-line ART, Second-line ART and lost from care). HIV diagnosis and linkage to care are modeled as separate health states to account
for lower rates of linkage to care among community-based HIV testing approaches compared to facility-based approaches.35 As test and
treat policy implementation improves in sub-Saharan Africa, separating HIV diagnosis and linkage may underestimate the benefits of
people starting ART on the same day. First- and second-line ART are modeled separately to account for more costly second-line ART
costs.36
Time horizon. We examined costs and health benefits using a lifetime horizon. A number of cost-effectiveness analysis studies in
literature using a Markov model have considered a lifetime time horizon while assessing efficiency of HIV prevention strategies.37–40
Cycle length: We used a monthly cycle length to account for timely linkage to care and ART initiation. The recommended time for
linkage to care and ART initiation after being diagnosed with HIV is 30 days. Although test and treat has been implemented in East and
Southern Africa,41,42 linkage to care is still low among hard-to-reach population and the cycle length of one month will account for the
timely linkage to care.43
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Discount rate: We discounted future economic costs and health benefits at 3% to convert future values to present values.1 People usually
value things more in the present than in future so by discounting we account for that time preference. Although the discount rate of 3%
is recommended by the WHO, there is less agreement on the true discount rate. 1 The application of a uniform discount rate overtime
may not be true given that other variables change overtime including preferences. 44 In sensitivity analysis, we assess the impact of the
discount rate on the incremental cost-effectiveness ratio by varying the discount rate between 0 and 5%.
Measure of effectiveness: Health benefits were measured as disability-adjusted life years (DALYs) averted. DALYs lost are the
recommended measure of health benefits in cost-effectiveness analysis conducted in low-income countries as they estimate the overall
burden of the disease (healthy life years lost due to both premature mortality and living with disability).1
DALYs is a standard measure of the burden of disease and can be compared across multiple conditions and cost-effectiveness analysis
(CEA) studies. Monthly disability weights came from Eaton et al.,29 and were derived from the global disease burden study.45 Disability
weights were applied to each health state based on the disease stage. All ART health states had the same disability weight regardless of
the disease stage to account for ART health benefits.
Study perspective: This study was conducted from a societal perspective. The World Health Organization recommends conducting
cost-effectiveness studies from a societal perspective, which takes into account direct health (e.g., clinical services and medications) and
non-health (e.g., patient time and transport cost to the healthcare facility) related costs of a health intervention for a society as a whole
regardless of who is paying.1 In this study, I included patient time spent at the healthcare facility to seek care and transport costs.

Parameter inputs
Initial distribution: An initial hypothetical cohort, 30-year-old, undiagnosed, individuals living with HIV is based on the CD4
distribution of newly diagnosed HIV individuals in Kenya.46 To our knowledge, no study has reported CD4 cell count distribution for
newly diagnosed female sex workers (FSWs) and truck drivers in Eastern and Southern Africa. We assumed the CD4 distribution
stratification in the general population would be comparable to that of FSWs and truck drivers.
Probability of disease progression: Data for disease progression came from a study conducted in south Africa that examined
community-based strategies to improve HIV care with parameter inputs derived from observational data.30 In our model, we assumed
that fractions of the cohort that experience disease progression are in undiagnosed, diagnosed, linked and lost health states. Those in
ART health states don’t experience disease progression due to the benefits of ART. Although fluctuations on CD4 cell count occur
among patients on ART, data to inform the parameters inputs were unavailable.
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Probability of death: Data for the probability of death among people living with HIV (PLWH) who are not on treatment came from a
longitudinal study in South Africa.47 Due to lack of CD4 cell count specific data in high-risk populations, we used data from PLWH in
the general population.47 For PLWH and on antiretroviral therapy (ART), we assume their mortality rate reduces by 58% compared to
those not on ART.48 Previous studies have shown that the impact of ART on population level mortality rate ranging from 25% 49 - 90%.50
Although gender variations in mortality rate in PLWH exist,51 we assumed that this variation is already accounted for in the background
mortality adjustment, thus ART is assumed to have an equal impact on men and women. In addition, the mortality rate was assumed to
be same for patients on first-line ART and second-line ART.52 We accounted for age and gender specific background mortality using
lifetables from the World Health Organization (WHO).53 The adjustment and calculation of monthly probability of death is done in three
steps:
1. Add the annual HIV mortality rate to the age-specific background annual mortality rate from the WHO.
2. Calculate the monthly mortality rate by dividing by 12
3. We convert the monthly mortality rate to probability of death.
The relationship between a rate and probability is expressed as: 𝑅𝑎𝑡𝑒 =

−ln (1−𝑝)
𝑡

, where r = rate, p = probability, t = time period.

Probability of being reached for HIV testing: The probability of being reached varied by the type of strategy (facility-based vs
community-based), gender (women vs men) and disease stage. Based on evidence from the general population, community-based
strategies are likely to reach more people including men, particularly those that are less likely to visit health-facilities for care (e.g., HIV
testing).54 We assume that truck drivers, whom the significant majority are men, are less likely to access care or be reached by facilitybased strategies compared to female sex workers who are women.55 For facility-based strategies, one study that interviewed truck drivers
at truck stops reported that only 36% of truck drivers used roadside wellness clinics for the past year, with 64% reporting either not
using the clinics or unaware of the roadside wellness clinics.56 We assume female sex workers are 50% more likely as truck drivers to
visit a health facility at least once within a year to seek care. For community-based strategies, we assume that both truck drivers and
female sex workers have the same likelihood of being reached. Based on a meta-analysis, 67% reported to have met or been reached by
a peer educator with a period of 12 months.57 Based on previous work done on truck drivers and female sex workers,58–61 a significant
majority are below 50 years. We assume that these individuals (50+ years) comparable access to care as people in the general population
and are likely to visit the health facility at least once a year due to multiple conditions that are prevalent within this age group.62,63
Probability of testing: This probability of testing varies based on the strategy, gender (men vs women), age and disease stage. Since
all truck drivers are men and female sex workers are women, we considered differences in their health care seeking behaviors are
compared to men and women in the general population. Probability of HIV testing by will vary age as strategies targeting high-risk
populations will only be applicable to 49 years and below those 50+ years old considered as part of the PLWH in general population
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and use the standard of care and are 50% less likely to test for HIV compared to those less than 50 years. 64 We assume that HIV testing
is offered ounce a year per strategy. We examined six alternative strategies including: 1) voluntary counseling and testing (VCT), 65 2)
provider-initiated and -administered HIV testing and counseling (PITC),66 3) peer educator direct delivery of HIV self-testing kits in the
community (HIVST Kit Delivery),67 4) peer educator delivery of coupons in community to exchange for an HIV self-test kit at the
healthcare facility (HIVST Coupon Delivery),67 5) peer educator referral to facility-based for a provider-administered HIV test (VCT
Referral),67 6) provider-initiated offer of oral HIV self-testing or provider-administered HIV testing (HIVST Choice).66 The HIVST
Choice and PITC are based on a randomized controlled trial conducted among 305 truck drivers in Kenya in 2015 that offered the choice
of provider-administered HIV testing or HIV self-testing at the clinic, or home vs only the provider-administered HIV testing.66 Three
other strategies (HIVST Kit Delivery, HIVST Coupon delivery, and VCT Referral) are based on a randomized controlled trial conducted
among FSWs in Uganda in 2017 that examined the effectiveness of HIV testing delivery strategies.67 The sixth strategy, VCT, is the
standard of care.65
Probability of testing among truck drivers
o Kit Delivery: The probability of HIV testing for the Kit Delivery strategy is based on an RCT conducted among FSWs
where 92.9% tested for HIV.67 Since self-testing is equally acceptable among men,54,68,69 we assume equal probability of
HIV testing among truck drivers. Although no study has been done among truck drivers, previous work done among men
who have sex with men (MSM) —a high-HIV-risk group— suggests that using peer-educators to distribute kits for HIV
self-testing at the healthcare facility is effective (95% uptake) at improving HIV testing.70
o Coupon Delivery: The probability of HIV testing for the Coupon Delivery strategy is also based on an RCT conducted
among FSWs where 76.8% tested for HIV.67 Although coupons are delivered in the community, individuals have to visit
the health facility to pick HIV self-test kits. For truck drivers, we assume that coupons are delivered to drivers at truck
stops and the probability of testing will be half (38.4%) of that of FSWs since men are less likely to visit the healthcare
facility to seek care as compared to women.
o VCT Referral: The probability of HIV testing for the Referral strategy is also based on an RCT conducted among FSWs
where 68.9% tested for HIV.67 Similar to the HIVST coupon delivery strategy, we assume that the probability for truck
drivers testing for HIV will be half (34.5%) of that of FSWs since it requires visiting the clinic to get tested for HIV.
o HIVST Choice: The probability of HIV testing is based on an RCT where truck drivers in the intervention were offered
the choice of provider-administered HIV testing or HIV self-testing at the clinic, or home vs only the provideradministered HIV testing.66 In the intervention, 87.3% of drivers tested for HIV.
o Provider-initiated and -administered: Similar to the HIVST Choice strategy, we use the control arm of the RCT 66 to
estimate the probability of truck drivers testing for HIV when the provider only offers the provider-administered test. In
the control arm, 72.9% of drivers tested for HIV.
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o VCT: Based on data from the RCT66, 40.5% of truck drivers who visited the clinic and agreed to participate in the study,
had specifically come to test for HIV and actually tested for HIV.
Probability of testing among female sex workers
o The probability of testing for HIV for the HIVST kit delivery; HIVST coupon delivery and VCT referral was based on
an RCT conducted among FSWs in Uganda where 92.9%, 76.8% and 68.9% tested for HIV, respectively. 67
o HIV self-testing Choice: Although no study has been conducted to offer a choice of self-testing in addition to the standard
of care among FSWs at the healthcare facility, previous work has shown high (95%) acceptability of oral self-testing
among FSWs.71,72 We assume that FSWs will likely have a high uptake of HIV testing when offered the choice of HIVST
compared to truck drivers.
o PITC: The probability of HIV testing among FSWs in this strategy was 90% based on previous work that has shown high
acceptability73–75 of HIV testing in FSWs at the healthcare facility, ranging from 74%74 to 100%75.
o VCT: This is the standard of care strategy and the probability of HIV test uptake is 23.4%. 60 The probability of VCT
testing for FSWs is lower than for truck drivers. This is counterintuitive given that women are more likely to use
healthcare services compared to men. Although FSWs are likely to visit the healthcare facility, they tend to seek care for
other health conditions but less for HIV prevention or HIV cares services. 60 A potential examination for this case could
be that many FSWs fear the stigma from the community being aware of their HIV status and health provider
discrimination. Alternatively, FSWs may be receiving HIV testing through during antenatal visits and also there are many
programs focusing on HIV testing and care for female sex workers compared to truck drivers.76
HIV test sensitivity: The sensitivity of the first HIV test is strategy specific, but the confirmatory test and tiebreaker test are the same
across all strategies. Strategies (HIVST Kit Delivery, HIVST Coupon Delivery and HIVST Choice) that offered the oral selfadministered test used the Oral Sure OraQuick test, sensitivity (95% confidence interval) = 92% (66.0 – 99.0).77,78 Strategies (VCT
Referral, HIVST Choice, PITC, VCT) that offered the blood-based provider-administered test used KHB colloidal Gold test, sensitivity
(95% CI) = 100.0% (97.4 – 100.0).79 The Self-testing Choice uses both the Oral Sure OraQuick and KHB colloidal Gold test for
individuals that tested using the self-administered test and provider-administered respectively. The sensitivity of the Self-testing Choice
strategy is a pooled estimate based on the percentage of individuals that tested using the self-administered (73%) and provideradministered test (27%).66 The HIV test algorithm in Kenya includes a confirmatory (First Response 1-2.0) and tiebreaker (Uni-Gold)
test, which have a sensitivity (95% CI) of 100.0% (97.4 – 100.0) and 96.4% (91.8 – 98.8).79
Probability of test results discloser and receipt of a confirmatory test: The probability of disclosing test results after taking an HIV
test varies based on the strategy setting (community-based vs facility-based). We assume that all (100%) individuals who test from the
health-facility and have a reactive test will disclose their results to the healthcare provider and also get a confirmatory test as
recommended in the HIV testing algorithm in Kenya.66,79 Previous studies conducted in the general population have reported wide
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variations on estimates for confirmatory test uptake. In Kenya, 60% of individuals were willing to get a confirmatory after an HIV selftest.80 One study that examined partner testing through distribution of self-tests suggested that more than 50% of those that tested positive
received a confirmatory test.81 In another study, only 25% (2 of 8 that tested positive) of individuals that tested positive received a
confirmatory test but the study couldn’t confirm if the other individuals received HIV care from another health facility. 82 In Malawi,
56% of individuals that self-tested received a timely confirmatory test.83 Little has been done in high-risk populations. In Kenya,
willingness to receive a confirmatory test was 40% and 75% among MSM and female sex workers, respectively. 80 In another study,
44%, 24% and 64% of female sex workers that had a positive reactive test in the kit delivery, coupon delivery and VCT visited the clinic
for HIV care.67 Among the community-based strategies examined in our study, they use peer-educators who followed up on the
individuals to make sure they used the HIV test and inquired to seek care if they tested positive. This may improve the percentage of
individuals getting a confirmatory test after a reactive test. We assume that 90% of those that test outside the healthcare facility will
seek timely care given that peer educators follow-up with nudge HIV positive individuals to seek care. The probability of discloser of
test results and receipt of a confirmatory test for the HIVST Choice strategy is a pooled estimate based on the percentage of individuals
that tested at health facility (91.5%) and home (8.5%).66
Probability of linkage to care: The probability of timely linkage to care67 was the same across all strategies but varies by disease stage.
All individuals, irrespective of the strategy, have to visit the health facility to get a confirmatory test before they considered diagnosed
of HIV.
Probability of ART initiation: The probability of ART initiation was the same across all strategies and doesn’t vary by disease stage
since based on the current guidelines of treat all.84 In Kenya, 83% of initiate ART within 30 days.85
Lost from care: The probability of loss from care varied by engagement in care (pre-ART and on ART), gender and risk.86–88 Although
studies have found advanced HIV disease stage (AIDS vs non-AIDS) has higher loss to follow up, the differences between AIDS vs
non-AIDS haven’t been statistically significant.86,88 Further, the higher loss to follow up in advanced disease stages may be a
misclassification of death as loss to follow-up.89–93 Evidence from people living with HIV in the general population shows that Pre-ART
patients have higher LTFU compared to ART patients, with Pre-ART patients nearly twice as likely as ART patients to be lost from
care.87 Since no study has examined differences in loss to follow up among high-risk populations, we base on general population
evidence87,94 to assume that Pre-ART patients are twice as likely as ART patients to be lost from care. Men are 1.5 times more likely to
be LTFU compared to women.86 Patients 50+ years old have a lower risk of LTFU compared to 49 years and below. 95
Costs: HIV testing costs (Table A1) include fixed costs (healthcare facility, equipment such as phones); medical costs (HIV test kit 43,96–
99 and medical supplies); personnel (medical and non-medical healthcare facility staff, and peer-educators), training, overhead costs,
and patient costs (patient time and transport to the health facility). The cost of a confirmatory and tiebreaker test were considered as an
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independent HIV test at a healthcare facility with all cost components of a standard HIV testing and counseling process applicable.27,79
The costs for the initial test in Kit delivery, Coupon delivery and VCT referral strategy came from the randomized controlled trial
report.43 Costs VCT and PITC came from a costing study on HIV testing in Kenya.99 Cost for patients in pre-ART and ART care came
from a report on costing analysis of compressive HIV care by the ministry of health in Kenya.100 All costs were estimated in three steps:
1. Convert costs from their original currency and year to Kenyan shillings
2. Convert costs to 2017 Kenyan shillings using the GDP deflator
3. Convert costs to 2017 international dollars
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Table S14: Advantages and disadvantages for the analytical decisions
Analytical decision Advantages
Using a
• Mathematical models enable the analyst to examine scenarios that
mathematical
would be more complex in the real-world setting. For example, I
model methodology
am able to examine alternative strategies that were implemented
in different settings at different time points, which would have
been impossible to implement in the real-world.
• Mathematical models enable the analyst to better understand the
impact of various degrees of variable on an outcome that would
be hard to change in the real-world setting.
• Mathematical models enable the analyst to project future
outcomes for various interventions. For example, in paper 2 and
3, I am able to project outcomes over a lifetime time horizon.
Using a single
• State-transition models provide the flexibility of examining
cohort state
economic costs and health benefits of alternative strategies, which
transition model.
may be costly or unethical to implement in the real world.
• State-transition models can evaluate hypothetical scenarios to
provide insight on outcomes of potential interventions if
implemented in the real world.
• State-transition models provide the flexibility to examine
outcomes of strategies beyond the time period of the existing data.
• State-transition models are straightforward to debug thus
minimizing potential coding error
Model structure:
Natural history
disease progression
as four CD4 strata

Disadvantages
• Mathematical models are usually
based on certain assumptions that
may not be realistic in a real-world
setting.

•

•

The clinical stages of HIV natural disease progression are defined •
based 4 CD4 cell count strata: Asymptomatic Early (corresponding
with CD4 count >500 cells/μL); Asymptomatic Late (>350 - 500
cells/μL); Symptomatic (>200 – 350 cells/μL); and AIDS (<200
cells/μL)).
• The 4 CD4 strata enables estimation of health benefits and
economic costs for early diagnosis and engagement in care vs
engagement in care at later stage of the disease. 30,32 Patients
diagnosed in early stages and immediately initiate ART

State transition models assume that
the probabilities are not dependent on
history (e.g., previous states or time
spent in a state), which is not always
the case.
The single cohort state transition
model does not capture individual
heterogeneity that reflects the real
world. Related approaches, such as
micro-simulation models, address
this limitation31
The CD4 stratification assumes
similar behavior for the whole
fraction of the cohort within the
stratum, which may not be the case.
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Model structure:
six-stage
engagement in HIV
care

•

•
Health benefits:
disability adjusted
life years (DALYs)
lost

•

•

Lifetime analytic
time horizon

•
•

Monthly cycle
length

•

experience lower risk of morbidity and mortality compared to
those that are diagnosed at late stages of the disease.33,34
HIV diagnosis and linkage to care are modeled as separate health •
states to account for lower rates of linkage to care among
community-based HIV testing approaches compared to facilitybased approaches.35
First- and second-line ART are modeled separately to account for
more costly second-line ART costs.36
DALYs lost are the recommended measure of health benefits in •
cost-effectiveness analysis conducted in low-income countries as
they estimate the overall burden of the disease (healthy life years
lost due to both premature mortality and living with disability).1
DALYs is a standard measure of the burden of disease and can be
compared across multiple conditions and CEA studies using
DALYs.
•

The lifetime horizon enables the analyst to capture future costs •
and health benefits of a strategy.
Cost-effectiveness analysis studies on this topic have generally
considered a lifetime time horizon. By implementing a similar
time horizon, our findings will be comparable to literature.37–40

Although test and treat has been implemented in East and •
Southern Africa,41,42 linkage to care is still low among hard-toreach population and the cycle length of one month will account
for the timely linkage to care.43

As
test
and
treat
policy
implementation improves in subSaharan Africa, separating HIV
diagnosis
and
linkage
may
underestimate the number of people
starting ART on time.
DALYs only measure the health
benefit of an individual without
accounting for the societal impact of
the disease. For example, it’s impact
on education and future
employment.101
The application of disability weights
in DALYs has been questioned due
lack of a valid standard measure
including the ethical aspect of
allocating statistical value on
someone’s life.101
Although a lifetime time horizon is
suitable for examining the impact of
strategies for chronic conditions
such as HIV, in the real world,
policy and other decision makers
typically have relatively short time
horizons for programmatic planning
and implementation goals (e.g., 5,
10 or 20 years).
In the era of test and treat, there is a
possibility of more than one event
(linkage to care and ART initiation)
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Discount rate of 3
percent

•

I discount future economic costs and health benefits to convert •
future values to present values.1 People usually value things more
in the present than in future so by discounting I account for that
time preference.
•

occurring within a one-month
cycle.43
Although the discount rate of 3% is
recommended by WHO, there is less
agreement on the true discount rate.1
The application of a uniform discount
rate overtime may not be true given
other variables change overtime
including
preferences
change
overtime.44
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Figure S1: Efficiency frontier for HIV testing strategies among female sex workers
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Figure S2: Efficiency frontier for HIV testing strategies among truck drivers
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Cost-effectiveness results for the base case analysis considering a payer perspective
Table S15: Discounted base case cost-effectiveness results¶
Domain*

HIV Testing Strategy

Costs ($)

Incremental
Cost ($)

DALYs
Lost

DALYs
Averted

ICER†

5.73
0.51

$ 364
$ 373

2.98

$ 374

Female Sex Workers
Health facility

Combination

Community

No Testing
Voluntary testing
Provider-initiated testing
HIVST Choice
HIV testing referral card
HIVST coupon delivery
HIVST kit delivery

$
$
$
$
$
$
$

1,405
1,854
3,491
3,682
4,359
4,385
4,797

$ 2,086
$
191

$ 1,114

21.93
20.70
16.20
15.69
13.88
13.83
12.70

Truck Drivers
Health facility

No testing
$ 1,425
22.11
Voluntary testing
$ 1,711
21.11
Provider-initiated testing
$ 2,152
19.99
Combination
HIVST Choice
$ 2,381
19.32
HIVST coupon delivery
$ 2,784
18.18
HIV testing referral card
$ 2,825
18.04
Community
HIVST kit delivery
$ 3,934
$ 2,509
14.77
7.34
$ 342
Abbreviations: HIVST = HIV self-testing, DALYs = Disability Adjusted Life Years, ICER = Incremental cost effectiveness ratio
*Strategies are classified by setting including health facility only, community only and a combination of both the health facility and
the community setting.
†ICER is expressed as incremental cost/DALYs averted.
§Compared to “No testing” strategy.
¶Costs (2017 $) and health benefits are discounted at 3% per annual.
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Scenario analysis: Assuming a FSW or truck driver will visit the health facility once a year
Table S16: Cost-effectiveness results when an individual visits a health facility at least once a year
Incremental
DALYs
DALYs
Domain*
HIV Testing Strategy
Costs ($)
Cost ($)
Lost
Averted

ICER†

Female Sex Workers
Health facility

Combination

Community

No Testing
Voluntary testing
HIV testing referral card
HIVST coupon delivery
HIVST kit delivery
Provider-initiated testing
HIVST Choice

$
$
$
$
$
$
$

1,405
3,442
5,503
5,535
6,107
6,154
6,297

$ 4,749

$ 143

21.93
17.93
13.88
13.83
12.70
12.59
12.32

9.34

$ 508

0.98

$ 530

Truck Drivers
Health facility

No testing
$ 1,425
22.11
HIVST coupon delivery
$ 3,331
19.82
HIV testing referral card
$ 3,391
18.19
Combination
Voluntary testing
$ 3,598
17.97
Provider-initiated testing
$ 4,553
18.05
HIVST Choice
$ 4,870
$ 3,445
17.11
7.18
$ 480
Community
HIVST kit delivery
$ 4,948
$ 78
14.78
0.15
$ 516
Abbreviations: HIVST = HIV self-testing, DALYs = Disability Adjusted Life Years, ICER = Incremental cost effectiveness ratio
*Strategies are classified by setting including health facility only, community only and a combination of both the health facility and
the community setting.
†ICER is expressed as incremental cost/DALYs averted.
§Compared to “No testing” strategy.
¶Costs (2017 $) and health benefits are discounted at 3% per annual.
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Supplementary materials for paper three
Table S17: Summary of the literature on PrEP effectiveness among hard-to-reach and general HIV populations
Intervention

PrEP
(Prospective
study design)

Hard to reach population
Intervention description
Population: Female sex workers
Country: Benin
Design: Prospective cohort
Sample size: 256
Year: 2018
Follow up time: 24 months
Primary outcome: HIV incidence
Secondary outcome: Adherence
(self-reported)
Study aim: To examine the impact
of PrEP (emtricitabine/tenofovir
disoproxil fumarate) on new HIV
infections.102
Population: Female sex workers
Country: South Africa
Design: Prospective cohort
Sample size: 219
Year: 2017
Follow up time: 12 months
Primary outcome: HIV incidence
Secondary outcome: Adherence
(self-reported)
Study aim: To examine the impact
of PreP (Truvada) on HIV
incidence in HIV negative
FSWs.104

Outcome, [range]
(95% CI)
HIV incidence =
0.8 (0.3-1.9) per
100 person years
Adherence =
[57—78%]

General population
Intervention description
Population: General population
(Serodiscordant Couples)
Country: Kenya and Uganda
Design: Prospective cohort
Sample size: 1013 couples
Year: 2012
Follow up time: 21 months
Primary outcome: HIV incidence
Secondary outcome: Adherence
(monthly drug count).
Study aim: To examine the impact
of PrEP (emtricitabine/tenofovir
disoproxil fumarate) on new HIV
infections.103

Outcome, [range]
(95% CI)
HIV incidence =
0.2 (0.0-0.9) per
100-person years
Adherence >85%

No new infections
Adherence
[70—85%]
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PrEP

Population: MSM
HIV incidence:
Country: Peru, Ecuador, South
1.08 vs 1.93 per
(RCT study
Africa, Brazil, Thailand, and US* 100 person years
design)
Design: RCT
in the intervention
Sample size: 2,499 (1,224 in
and control
intervention and 1,217 in control)
respectively.
Year: 2010
Follow up time: 34 months
Efficacy
Primary outcome: HIV incidence
(TenofovirSecondary outcome: Adherence
emtricitabine)
(self-reported)
44% (15 – 63)
HIV negative MSM were recruited
to examine the impact of daily
Adherence=95%
emtricitabine and tenofovir
(Not different
disoproxil fumarate on preventing across groups)
new HIV infections.105
Population: Injection drug users
HIV incidence:
Country: Thailand
Design: RCT
Tenofovir
Sample size: 2,413 (1,204 in
0.35 (0.21-0.56)
tenofovir &1,209 in placebo
Vs Placebo
group)
0.69 (0.47 – 0.96)
Year: 2013
per 100 person
Follow up time: 84 months
years
Primary outcome: HIV incidence
Secondary outcome: Adherence
Efficacy
(drug dairies)
(Tenofovir)
An RCT among injection drug
48% (10 – 72)
users examined impact of
Adherence=84%
(tenofovir) on the risk of getting
(Not different
HIV compared a placebo.107
across groups)
*The number of participants from the US was less than 10%.

Population: General population
Country: Kenya and Uganda
Design: RCT
Sample size: 4,747 (1,584 in
tenofovir; 1,579 in tenofoviremtricitabine and 1,584 in the
placebo group)
Year: 2012
Follow up time: 36 months
Primary outcome: HIV incidence
Secondary outcome: Adherence
(monthly drug count).

HIV incidence:
1.99 vs 0.65 vs 0.5
per 100 personyears for placebo,
Tenofovir and
tenofoviremtricitabine,
respectively.

The aim of the study was to
examine the impact of PrEP on new
infections.106
Population: General population
Country: Botswana
Design: RCT
Sample size: 1,219 (611 in
tenofovir-emtricitabine and 608
placebo group)
Year: 2012
Follow up time: 45 months
Primary outcome: HIV incidence
Secondary outcome: Adherence
(drug count).

Adherence = 92%
(Not different
across groups)
HIV incidence:
Tenofoviremtricitabine - 1.2
Vs placebo – 3.1
per 100 person
years.

The study aim was to examine the
impact of PrEP on new HIV
infections.108

Adherence=84.1%
(Not
different
across groups)

Efficacy
(Tenofovir)
67% (44 – 81)

Efficacy
(Tenofoviremtricitabine)
62% (21 – 84)
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Table S18 show supporting evidence that adherence on ART and PrEP are comparable to further justify the decision to use PreP as a
proxy measure of behavior for individuals on ART.

Table S18: Systematic reviews and meta-analyses examining adherence to ART vs adherence to PrEP
ART adherence
Study description
Design: Meta-analysis and systematic
review
Sample size: 146 studies
Year published: 2016
Outcome: Adherence
Study aim: To examine determinants
of adherence to antiretroviral therapy
in sub-Saharan Africa.109
Design: Meta-analysis and systematic
review
Sample size: 50 studies
Year published: 2014
Outcome: Adherence
Study aim: To examine levels of
adherence to antiretroviral therapy
among adolescents.111
Design: Meta-analysis and systematic
review
Sample size: 14 studies
Year published: 2019
Outcome: Adherence
Study aim: To examine impact of
antiretroviral therapy adherence
interventions among women living
with HIV.113

Adherence estimate
(95% CI), [Range]
72.6% (Pooled
average adherence
across studies)

84% (79–89) (Pooled
average adherence
across studies)

75% [48-79] (Median
adherence across
studies)

PrEP adherence
Study description
Design: Meta-analysis and systematic
review
Sample size: 7 studies
Year published: 2016
Outcome: Adherence
Study aim: To examine the efficiency of
PreP in preventing HIV-1 infection among
women.110
Design: Meta-analysis and systematic
review
Sample size: 13 studies
Year published: 2017
Outcome: Adherence
Study aim: To examine the efficiency of
PreP in preventing HIV-1 infection among
adolescents.112
Design: RCT*
Population: MSM and Female sex
workers
Year published: 2012
Outcome: Adherence
Study aim: To examine adherence and
safety of PrEP among MSM and female
sex workers in Arica.114

Adherence estimate
(95% CI), [Range]
Range (66-81%)

Range (51-82%)

Adherence varied
based on
measurement method.
Daily medication
event monitoring
system for daily
dosing - 83% [IQR:
63–92]
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Design: Meta-analysis and systematic Older adults - 72%
Design: systematic review
Range (67-83%)
review
Young adults - 68%
Sample size: 13 studies
Sample size: 20 studies
Year published: 2016
Year published: 2019
(Pooled average
Outcome: Adherence
Outcome: Adherence
adherence across
Study aim: To examine the efficiency of
Study aim: To examine differences in studies)
PreP in preventing HIV-1 infection in
antiretroviral therapy adherence
women.116
between older adults with younger
adults in Africa.115
*This study was considered because it only focused on high-risk populations (MSM and FSW) and there is no meta-analysis that only
considered these populations.
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Table S19: Potential candidate cost data for LTFU strategies and ART-related costs to inform economic unit costs
Cost Component
Community health
worker salary

One-time training for
community health
worker
Community health
worker transport
Clothing for
community health
worker
Management and
administration for
community health
workers
Monitoring and
evaluation for
community health
workers program
Salary for tracker –
tracing patients
Expenses for tracing
patients
Expenses for tracing
patients

Country

Year of
data
2007
2012
2012

USD
USD
USD

Per month
Per patient month
Per month

Original estimate
(range)
35.00 (2.00 – 75.00)
(1.88 – 3.43)
63.00 (2.00 – 294.00)

2014
2014
2014
2014
2012

USD
USD
USD
USD
USD

Per month
Per month
Per month
Per month
Per patient year

100.00
46.00
23.00
40.00
5.97

120

Uganda

2007

USD

Daily

3.00

117

South Africa

2012

US

Per patient year

0.15

121

South Africa

2012

USD

Per patient year

0.48

121

South Africa

2012

USD

Per patient year

0.10

121

South Africa
South Africa
South Africa

2010
2010
2010

USD
USD
USD

Per patient month
Per patient month
Per patient month

3.70
2.14
0.57

122

South Africa

2010

USD

Per patient month

0.57

122

Uganda
South Africa
Sub-Saharan
Africa
Malawi
Ethiopia
Kenya
Mozambique
South Africa

Currency

Unit costs

Source
117
118
119

121

122
122
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Rwanda
Uganda
Senegal
Mozambique
Côte d’Ivoire

2006
2010
2017
2009
2006

USD
USD
USD
USD
USD

Per patient year
Per patient year
Per patient day
Per patient 3months
Per patient month

128.00
538.00
0.99
140.26
1.00
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ART-related costs sources
Health Facility staff
South Africa
Uganda
Uganda
Uganda
Kenya
Overhead costs
South Africa
Uganda
Uganda
Uganda
Kenya
Health Facility and
South Africa
Equipment
Uganda
Kenya
Laboratory costs
Uganda
Rwanda
Malawi
Ethiopia
Zambia
Zambia
Uganda
Kenya
Opportunistic
Uganda
infections
Burkina Faso
South Africa
Ghana

2012
2012
2010
2016
2011
2012
2012
2010
2016
2011
2012
2016
2011
2012
2012
2012
2012
2012
2010
2010
2011
2012
2008
2009
2012

USD
USD
UGX
USD
USD
USD
USD
UGX
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
USD
UGX
USD
USD
USD
USD
USD

Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient year
Per patient month
Per patient year
Per patient year

0.48
65.54
55,000
51.08
38.44
0.99
47.09
85,000
5.33
17.63
0.02
6.57
9.08
20.94
15.00
5.00
16.00
13.00
69.94
111,000.00
19.30
42.85
0.60
96.00
(9.94 – 39.86)

121

Nutrition support to
patients

Breakfast

124
125
126
127

128
129
130
100
121
128
129
130
100
121
130
100
128
131
131
131
131
132
129
100
128
133
134
135
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Kenya
2011
USD
Per patient year
8.51
Uganda
2010
UGX
Per patient year
11,000.00
Opportunity cost of
Ghana
2009
USD
Per patient month
2.74
time for seeking care South Africa
2010
USD
Per patient month
12.04
Côte d’Ivoire
2014
USD
Per patient month
9.38
Kenya
2011
USD
Per patient month
2.83
Transport to the clinic South Africa
2009
USD
Per patient month
6.00
South Africa
2017
USD
Per patient month
2.80
Uganda
2010
UGX
Per patient year
7,069.00
Uganda
2007
USD
Per patient month
(1.75 – 11.50)
Uganda
2015
USD
Per patient month
1.89
Kenya
2011
USD
Per patient year
33.80
First line ART
TDF/3TC/EFV LIC
2017
USD
Per patient year
90.00
LIC
2016
USD
Per patient year
100.00
TDF/FTC/EFV LIC
2017
USD
Per patient year
90.00
LIC
2016
USD
Per patient year
106.00
AZT/3TC/EFV LIC
2016
USD
Per patient year
164.00
Second Line ART
AZT+3TC+ATV/r LIC
2017
USD
Per patient year
233.00
LIC
2016
USD
Per patient year
286.00
Abbreviations: LIC = Low-income countries; CHAI = Clinton Health Access Initiative; MSF = Medecins Sans Frontieres

100
129
136
137
138
100
122
139
129
140
141
100

36
142
36
142
142

36
142
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Table S20: Cost-effectiveness results associated with different initial distributions
Initial Distribution

Strategy
Cost
Incremental cost DALYs Lost
DALYs Averted ICER
No Intervention
$ 2,449.59
9.98
ART delivery
$ 3,087.43
$
637.83
9.02
0.96
$ 660
Tracing + Transport
$ 3,732.24
9.53
Medical care + Transport + Breakfast $ 4,110.88
8.99
All cohort with
Tracing + Medical care
$ 4,681.14
8.81
CD4>500
ART delivery + Nutrition
$ 9,849.08
$ 6,761.65
7.60
1.42
$ 4,700
No Intervention
$ 2,859.77
10.69
ART delivery
$ 3,437.80
$
578.02
9.55
1.15
$ 500
All cohort with
Tracing + Transport
$ 4,258.12
10.15
CD4 500 - >350
Medical care + Transport + Breakfast $ 4,571.81
9.51
Tracing + Medical care
$ 5,167.03
9.30
ART delivery + Nutrition
$ 10,418.27 $ 6,980.47
7.92
1.63
$ 4,300
No Intervention
$ 3,409.62
11.68
ART delivery
$ 3,919.99
$
510.37
10.28
1.40
$ 360
All cohort with
Tracing + Transport
$ 4,976.13
11.00
CD4 >350 - <200
Medical care + Transport + Breakfast $ 5,208.80
10.23
Tracing + Medical care
$5,841.41
9.99
ART delivery + Nutrition
$ 11,221.68 $ 7,301.70
8.37
1.91
$ 3,800
No Intervention
$ 3,323.55
13.40
ART delivery
$ 3,528.45
$
204.90
12.78
0.62
$ 330
Tracing + Transport
$ 4,701.29
13.07
Medical care + Transport + Breakfast $ 4,702.99
12.77
All cohort with
Tracing + Medical care
$ 5,206.65
12.69
CD4 ≤200
ART delivery + Nutrition
$ 9,156.46
$ 5,628.00
12.27
0.51
$ 10,900
>500
= 0.42 No Intervention
$ 3,018.00
11.77
500 - >350 = 0.25 ART delivery
$ 3,446.14
$
428.15
10.86
0.91
$ 470
>350 - <200 = 0.21 Tracing + Transport
$ 4,398.94
11.32
≤200
= 0.12 Medical care + Transport + Breakfast $ 4,588.11
10.83
Tracing + Medical care
$ 5,143.12
10.68
ART delivery + Nutrition
$ 9,842.42
$ 6,396.28
9.72
1.14
$ 4,800
Abbreviations: ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER = Incremental cost-effectiveness ratio
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Table S20 shows results for the variation of the initial distribution. Results were consistent with the baseline findings. ART Delivery
was cost-effective with an ICER less than $700 compared to No Intervention when all the initial cohort was assumed to start at CD4
strata >500, 500 - >350, <350 - >200 and ≤200. Further, ART Delivery with nutrition supplement was cost-effective at a WTP
threshold of 3xGDP of Kenya ($4,700), when all the initial cohort started at CD4 strata >500, 500 - >350 and <350 - >200 but not
≤200. This suggests that ART Delivery with nutrition supplement maybe cost-effective in reducing LTFU if FSWs living with HIV
are on treatment at early stages of HIV.
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Figure S3: Efficiency frontier for LTFU strategies in the base case analysis
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Figure S4: Cost-effectiveness results when we assume nutrition supplement is offered for only 5 years
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Table S21: Cost-effectiveness results when we assume nutrition supplement is offered for only 5 years
Incremental
cost

DALYs
DALYs
Strategy
Cost
Lost
Averted
ICER
No Intervention
$ 2,994.56
11.52
ART delivery
$ 3,460.73 $
466.17
10.55
0.98
$ 470
Tracing + Transport
$ 4,386.60
-11.05
abs. dominated
Medical care + Transport + Breakfast $ 4,606.21
-10.51
ext. dominated
Tracing + Medical care
$ 5,173.28
-10.35
ext. dominated
ART delivery + Nutrition
$ 5,263.00 $ 1,802.00
10.12
0.42
$ 4,300
Abbreviations: ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER = Incremental cost-effectiveness ratio
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Figure S5: Cost-effectiveness results when we assume nutrition supplement is offered for only 10 years
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Table S22: Cost-effectiveness results when we assume nutrition supplement is offered for only 10 years
Incremental
cost

DALYs
DALYs
Strategy
Cost
Lost
Averted
ICER
No Intervention
$ 2,994.56
11.52
ART delivery
$ 3,460.73 $
466.17
10.55
0.98
$ 470
Tracing + Transport
$ 4,386.60
-11.05
abs. dominated
Medical care + Transport + Breakfast $ 4,606.21
-10.51
ext. dominated
Tracing + Medical care
$ 5,173.28
-10.35
ext. dominated
ART delivery + Nutrition
$ 6,354.00 $ 2,893.00
10.12
0.42
$ 6,880
Abbreviations: ART = Antiretroviral Therapy; DALYs = Disability Adjusted Life Years; ICER = Incremental cost-effectiveness ratio

161

Figure S6: Cost-effectiveness acceptability curves for LTFU strategies
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